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Abstract 
 
Role of Nuclear Factor Kappa B (NFĸB) in the vascular complications of 
diabetes 
Fatima Mohamed Al Ali  
for the degree of Master of Research (MRes) 
 
Diabetes mellitus (DM) is the most common metabolic disease 
worldwide. This condition accounts for the majority of renal failure and 
blindness in adult’s aged between 20 to 74 years of age. After 20 
years, some of type 1 diabetic patients and around 60% of type 2 
diabetic patients will be diagnosed with retinopathy. In 2011, a survey 
was presented and supplied data on the number of people who are 
suffering from diabetes. In Scotland, they found that 247,278 people 
were diagnosed with diabetes. In addition, about 36.6% of patients’ 
were diagnosed with type 1 diabetes (T1DM) and 31.7% of those with 
type 2 diabetes (T2DM).  
In this research, the role of inflammatory mediators in the progression 
of the vascular complications of diabetes was investigated. Specifically, 
the role of nuclear factor kappa B1 (NFĸB1). There were 2 approaches 
used in this study: i) a bioinformatics approach to determine what 
single nucleotide polymorphisms (SNP) may occur within the NFĸB1 
gene in T2DM and ii) a molecular biology approach to investigate the 
role of the SNP of interest in a human monocyte cell line using 
polymerase chain reaction (PCR) and restriction enzymes.  
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Methods 
Genetic polymorphisms were investigated using bioinformatics tools 
through computational analysis and databases, such as, Ensembl and 
the National Center for Biotechnology Information (NCBI), NEB cutter, 
Primer Quest and NetPhos. The SNP of interest was identified due to its 
role in diabetes. Primers were designed to span the region for the SNP 
of interest, amplified using PCR and resolved in an agarose gel.   The 
SNP of interest was restricted with three restriction enzymes 
(HpyCH4iii, Alu1 and PvuII) followed by sequencing of the product. The 
U937 monocyte cell line was used to investigate the expression of the 
NFĸB gene. Cells were incubated in RPMI 1640 with 2 mM L-glutamine, 
100 U/mL Penicillin, Streptomycin and 10% heat inactivated foetal 
bovine serum (FBS) with H2O2 for up to 180 minutes with 5.5mM, 
20mM and 40mM glucose +/- H2O2.  RNA extraction was followed by 
cDNA amplification, which was subsequently used in reverse 
transcriptase polymerase chain reaction (RT-PCR) and for a period of 
time to address the biological significance of NFĸB activation in these 
conditions.   
 
Results 
 A DNA fragment corresponding to the 206bp fragment was identified 
that spanned the area containing the SNP.  Successful restriction with 
HpyCH4iii has not been possible, therefore, DNA sequencing was 
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carried out.  Sequencing identified the A allele indicating the presence 
of the homozygous wild type form of this region. 
Also, determining the role of NFĸB activation, HIF1-α and β2-
microglobulin in U937 cells mRNA via culturing U937 under high 
glucose (HG) condition in different concentrations (5.5mM, 20mM and 
40mM). The NFĸB and β2-microglobulin PCR product was not detected 
during incubations with various glucose concentrations.  
 
Conclusion 
The DNA sequence of the U937 cell line corresponds to the wild type 
form of the SNP under investigation.  This model has enabled the 
investigation of the effect of glucose concentration on the expression of 
the NFB and HIF1 genes and this has provided useful insight that 
can be used to develop this work further. 
 
Keywords: diabetes, type 1 diabetes, type 2 diabetes mellitus, diabetes 
retinopathy, pathogenesis of diabetes, nuclear factor kappa B (NFKβ1), 
bioinformatics, U937 cell line, SNP detection, rs230539. 
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This thesis shall present work relating to the role of nuclear factor 
kappa B1 in the vascular complications of diabetes. This work has been 
carried out through investigation of genetic polymorphisms within the 
NFĸB1 gene using in silico analysis and investigation of the regulation 
of NFĸB1 mRNA in a human monocyte U937 cell line. This chapter 
begins with an overview of diabetes in term of causes, types and the 
role of mechanistic pathways. Secondly, an overview of nuclear factor 
kappa B and the relationship between NFĸB and diabetes will be 
presented followed by a description of the rationale for this study. 
 
1.1 Diabetes 
 
Diabetes mellitus (DM) and diabetes insipidus (DI) are both chronic 
medical conditions.  DM is caused by insulin deficiency and/or insulin 
resistance, whereas, DI is an insufficiency of vasopressin secreted 
through the pituitary gland (Di Iorgi et al. 2012). Diabetes mellitus is 
classified into two forms: Type 1 and Type 2 (Allman 2008).  
 
1.1.1 Type 1 diabetes mellitus  
Type 1 diabetes mellitus (T1DM), also known as insulin-dependent 
diabetes, is characterised by damage to the pancreatic β-cells, which is 
often caused by autoimmune processes such as autoantibodies to 
insulin (Faideau et al. 2005). Within the pancreatic islets of 
Langerhans, autoantibodies bind to  cells, which in turn stimulate T 
cells leading to the autoimmune destruction of these cells and thus the 
loss of insulin production which results in T1DM (Faideau et al. 2005). 
Insulin is released from the pancreas into the bloodstream, and is 
responsible for, not only, controlling how the body utilises 
carbohydrate and fat found in food, but also for the regulation of the 
metabolism of glucose absorbed into the bloodstream from food. T1DM 
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is characterised by insulitis, which may result in islet cell inflammation 
and also in β-cell damage. During T1DM, the inflammatory lesion 
occurs inside islets and these were identified by the absence of insulin 
production and cause an increase in the number of cells that are 
responsible for the immune response including T-lymphocytes, B 
lymphocytes and macrophages (Atkinson 2012). 
 
1.1.2 Type 2 diabetes mellitus  
Type 2 diabetes mellitus (T2DM), previously known as adult onset or 
non-insulin-dependent diabetes, is diagnosed when an inadequate 
amount of insulin is released and/or the insulin being released is 
ineffective in target tissues such as muscle and liver cells (Williamson 
2009),  precipitating a condition known as insulin resistance (Aiello 
2002; Alghadyan 2011).  This results in high levels of circulating 
glucose. The incidence of T2DM is known to increase with age, 
adiposity and genetic factors and, there are also lifestyle aspects, such 
as, obesity that can contribute to the onset and the progression of this 
condition (Ma & Chan 2013). 
 
1.1.3. Diabetes insipidus  
Diabetes insipidus (DI) is a kidney disorder which is in contrast to 
T1DM. In DI, high blood sugar is not present and immoderate 
urination, which is caused by inadequate supplies of the anti-diuretic 
hormone (ADH) that known as vasopressin, can lead to an increased 
salt concentration (Di Iorgi et al. 2012). It is a kidney disorder that is 
caused by insufficient vasopressin released by the pituitary gland 
(Serono 2011).
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1.1.4 Vascular complications of diabetes mellitus 
T1DM and T2DM are health conditions associated with blood glucose 
concentrations that are raised to a level that adversely influences the 
body’s physiology and the function of a variety of organs, including the 
kidneys, eyes and heart (Allman 2008).  
There are two main types of complications associated with DM, namely 
macrovascular and microvascular complications. Macrovascular 
complications affect large vessels such as cardiac and cerebrovascular 
vessels, triggering the process of atherosclerosis, which leads to the 
narrowing of arterial walls throughout the body (Fowler 2008). 
Microvascular complications, according to Chistiakov (2013), affect the 
small vessels in the eyes, kidneys and other vital organs of the body, 
leading to a multiplicity of complications including diabetic retinopathy, 
neuropathy and nephropathy. Prolonged hyperglycemia is a major 
cause of vascular complications that are associated with diabetes (Cade 
2008). Hyperglycemia activates oxidative stress, which has a role in 
enhancing vascular complications. Extant literature demonstrates that 
the most common microvascular complication is diabetic retinopathy 
(Sivaprasad et al. 2012) and this particular vascular complication will 
be the focus of this thesis. 
 
1.2  Diabetic retinopathy 
 
Diabetic retinopathy (DR) is the leading cause of blindness among the 
adult population (Chistiakov 2011). A common complication in T1DM 
patients after diagnosis is DR; and current statistics demonstrate that 
over 60% of individuals presenting with T2DM will also suffer from DR 
(Saxena 2012). Furthermore, a recent study conducted in the United 
Kingdom shows that 60% of patients with type 2 diabetes are affected 
by retinopathy (Diabetes UK 2010).  
15 
 
DR is sub-classified into two stages: an early non-proliferative stage 
and a later proliferative stage. During the early stages, pericyte 
deficient capillaries and saccular capillary microaneurysms are 
identified. As posited by Saxena (2012), mechanisms for retinal 
capillary retrogression include the blockage by white blood cells or 
platelets of the vessel lumen, leading to endothelial cell death and 
capillary destruction. In DR, high concentrations of glucose accumulate 
inside blood vessels of the retina and in other tissues leading to a 
complex series of changes to biochemical pathways leading to 
functional changes (Kerry 2013).  
The most common characteristics of non-proliferative DR include 
haemorrhages, microaneurysms, microinfarcts and the production of 
exudates. The first sign of retinopathy is a microaneurysm, which 
manifests as an enlargement of the capillary wall and appears as small 
red dots on the retina (Alghadyan 2011). Small caliber retinal vessels, 
such as arterioles and capillaries, are the main casualties in diabetic 
retinopathy, with research showing that the damage causes 
microvascular occlusion, which in turn leads to hypoxia and the 
development of new vessels (Saxena, 2012). Macular oedema, 
according to this particular author (Saxena, 2012), also results from 
microvascular leakage. Blood vessels consist of two types of interacting 
cells. One of these cells is endothelial cells, which form the inner lining 
of the vessel wall and the other cell type is the pericyte (Saxena, 
2012). 
Pericytes are a specialised type of vascular smooth muscle cell that can 
be found in close association with blood capillaries. The normal retina 
has a high pericyte density. Diabetic patients are likely to develop DR 
and this loss of pericytes cells is an early feature of diabetic 
retinopathy. The reason for pericyte damage is thought to be 
hyperglycemia when damage leads to serious effects, which cause 
microaneurysms and weakness of the vascular walls (Bergers & Song 
2005).   
The presence of abnormal retinal vessels triggers the leakage of 
proteins and lipoproteins, not to mention the bursting of weak 
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capillaries often causes haemorrhages that appear in the deep layer of 
the retina (Alghadyan 2011). The progression of new vessels on the 
optic disk also occurs in proliferative diabetic retinopathy (PDR). 
Neovascularization and preretinal haemorrhage are the first signs of 
early PDR, with neovascular glaucoma following in late phases of 
disease progression (Alghadyan 2011). 
Animal studies show that pericytes vanish before endothelial cells are 
lost and acellular capillaries with no blood supply remain (Hammes et 
al. 2011). Thus even before endothelial damage is evident the vessel 
function is compromised. The leakage of retinal capillaries and the 
associated ischemic retina increases the potential for an angiogenic 
response from the surrounding areas of capillaries leading to PDR 
(Hammes et al. 2011).  
Monocyte accumulation may also participate in the progression of DR 
and can lead to neovascularization and a detached retina (Marumo et 
al. 1999). There is an important growth factor known as vascular 
endothelial growth factor (VEGF) that is associated with DR and has a 
vital role in progression of diabetic complications (Marumo et al. 1999). 
In addition, hyperglycemia causes a rise in VEGF expression in aortic 
smooth muscle cells (Duh & Aiello 1998). VEGF is a moderator of 
vascular permeability and angiogenesis in the pathogenesis of DR 
(Andreasen et al. 2011). 
VEGF is one of the main growth factors that act during angiogenesis, 
which is central for the creation of new blood vessels (Roy 2006). 
Angiogenesis is activated by VEGF in several pathological conditions 
such as tumor growth, wound healing, cardiovascular disease, 
embryogenesis and ocular neovascularisation. An increased level of 
VEGF-A expression has been the consequence in DR in humans (Roy 
2006) with elevated levels of VEGF-A resulting in vascular leakage and 
neovascularization in DR (Roy 2006). The failure of the vascular wall in 
diabetes is the consequence of chronic hyperglycemia. Therefore, 
chronic hyperglycemia is a key factor for vascular dysfunction. 
Advanced glycation end products pathway (AGEs) result from increased 
blood glucose levels. Increased accumulation of AGEs takes place in the 
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vasculature. AGEs influence blood vessels by different receptor 
pathways such as macrophage scavenger receptor (MSR) type II, 
galectin-3, CD36 and receptor for AGEs (RAGE). For instance, 
interaction between AGE and RAGE (AGE-RAGE) activates the 
expression of pro-inflammatory molecules and NFĸB. In addition, AGE 
and RAGE interact with several ligands such as amyloid-β peptide, 
macrophage-1 antigen (MAC-1) and this interaction causes the 
activation of the mitogen-activated protein kinase (MAPK p38) 
pathway. Expression of these molecules contribute to the progression 
of vascular complications (Roy 2006).  
Large vessels are composed of vascular smooth muscle cells (VSMCs), 
endothelium and adventitia. VSMC has an important role in controlling 
of blood pressure, for that reason, VSMC layers decrease with vessel 
size and are not present in the capillary. The high numbers of pericytes 
are important when considering endothelial proliferation, regulation and 
angiogenesis and have a role in the  support of the endothelium 
(Andreasen et al. 2011). 
The risk of DR may be controlled to an extent with good diabetes 
management and the sight-threatening disease may be treated by laser 
photocoagulation and vitrectomy (Tarr et al. 2013) but, clearly an 
alternative approach is needed. 
 
1.3. Diabetic retinopathy and the immune 
response 
 
Several intriguing findings from studies containing patient samples and 
animal models show that DR is associated with chronic inflammation:  
including cytokines and chemokines, which in turn activate leukocytes 
and endothelium (King 2008). In addition, according to King (2008), 
there are diverse inflammatory shifts associated with DR, including 
increased cytokine levels and adhesion molecules, as well as mounting 
vasocclusion. Evidence indicates that leukocytes can block capillaries 
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and this is a result of the huge size of these cells in relation to the size 
of the capillaries and the stiffness of the cytoplasm (Schröder et al. 
1991). Endothelial cells enlarge and the capillary tightens in conditions 
of low perfusion pressure and during the early stages of diabetes 
(Schröder et al. 1991). The release of chemotactic factors and 
expression of adhesion molecules on endothelial cells can lead to 
increasing adhesive stress between the endothelium and leukocytes. 
The stimulation of monocytes is associated with the production and 
release of oxygen free radicals and proteases. This activation leads to 
microvascular injury (Schröder et al. 1991). Indeed, some experiments 
show that tumor necrosis factor alpha (TNF-α) and interleukin-1 beta 
(IL-1β) are elevated in the serum of patients suffering from DR (Nehme 
& Edelman 2008). Consequently, the stimulation of these cytokines is 
inarguably associated with the pathogenesis of DR, which in effect is 
stimulated by an increase of glucose level in human monocytes (Nehme 
& Edelman 2008). An animal study (in diabetic rats) (Schröder et al. 
1991) shows that monocytes cluster within the DR lesion, which 
indicates that monocyte recruitment is increased through disease 
progression. Hyperglycemia has been reported to encourage expression 
of inflammatory molecules such as IL-6, IL-8, vascular cell adhesion 
molecule 1 (VCAM-1) and monocyte chemoattractant protein 1 (MCP-1). 
Also, there are endothelial alterations caused by hyperglycemia such as 
increasing adhesion molecule expression that enhance platelets and 
monocyte adhesion to the endothelium. Increased activity of 
endothelial cells causes monocytes to move into the vascular tissue, 
which transform to a macrophage. The macrophages act as a local 
source of  pro-inflammatory molecules (Andreasen et al. 2011).  
Immunity within the retina is critical during infections and 
inflammation. There is a special cell in the retina known as the retinal 
pigment epithelium (RPE), which in turn has an important role in 
immune defense. The RPE is composed of one layer of neural cells, 
which are located among the neural retinal photoreceptors and choroid 
cell (Detrick et al. 2010). There are several functions for the RPE cells 
including nutrient transportation from the choroid to the retina and 
transfer of waste in the opposite direction. The role of this cell is as an 
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antigen presenting cell (APC) that regulates both innate and adaptive 
immune responses. Therefore, they express Toll-Like receptors (TLRs), 
complement components, Fc-gamma receptors and major 
histocompatibility complex (MHC) class I and II molecules. This leads to 
the production of cytokines, chemokines, and growth factors and 
proinflammatory molecules including, IL-6, IL-8, MCP-1, and sICAM-1. 
IFN-β is highly expressed by the RPE cell (Detrick et al. 2010).  
There are some studies that show that TGF-β stimulates RPE cells to 
produce VEGF and can inhibit T-cell function (Detrick et al. 2010). 
Moreover, the RPE cell produces suppressive molecules including TGF-
β, IL-11, and IFN-β cell (Detrick et al. 2010). In addition, the basic site 
for retinal changes and damage is the RPE cell, which has significant 
effects in optical diseases such as DR (Detrick et al. 2010). 
NFĸB located in microvessels of the retina and its stimulation is in 
charge of pericyte damage in DR (Song et al. 2012).The activity of 
NFκB is operated through phosphorylation , which induced degradation 
of  regulatory proteins, which are known as NFκB inhibitors (IκB) 
(Sandip 2009). There are several members of IκB family: IκBα, IκBβ, 
IκBγ and Bcl-3. These members have 33 amino acid sequences known 
as ankyrin repeats, which intermediately attach to NFκB dimers and 
increase the activity of NFκB (Sandip 2009).  
NFκB is activated when IκB is degraded. Through this stimulation, IκBα 
is phosphorylated on serine residues by IκB kinase. Phosphorylation 
leads to the production of IκBα, which is a substrate for ubiquitination 
on lysine residues. This molecule causes degradation of the protein by 
the 26S proteasome (Donnelly, et al. 2004). 
 
1.3.1  Pathogenesis of diabetic retinopathy 
There is a study that shows that most of T1DM patients and ›60% of 
T2DM patients can suffer from DR (Tarr et al. 2013).Several factors, 
including age, control of glycaemia, pregnancy, control of blood 
pressure, renal failure and hyperlipidemia (abnormally elevated levels 
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of any or all lipids and/or lipoproteins in the blood stream), are known 
to contribute to the initiation and progression of DR. Moreover, 
biochemical shifts play a considerable role in the occurrence of 
hyperglycemia (Alghadyan 2011). Alghadyan (2011) acknowledges the 
existence of several biochemical changes, including increased polyol 
pathway flux, activation of protein kinase C (PKC), elevation of 
oxidative stress, formation of AGEs and activation of hexosamine 
pathway. These important pathways are briefly described below as they 
relate to DR and are the subject of a hypothesis suggested by Michael 
Brownlee (Brownlee 2005). 
 
1.3.1.1 Polyol pathway flux 
 
This is a metabolic pathway where glucose is converted into sorbitol by 
the enzyme aldose reductase (AR), using as a co-factor nicotinamide 
adenine dinucleotide phosphate (NADPH) (as shown in Fig 1). Sorbitol 
dehydrogenase oxidises sorbitol to fructose and nicotinamide adenine 
dinucleotide (NAD+) (Aveleira 2009). Researchers have found that AR 
is involved in diabetes, particularly in reference to the observation that 
in hyperglycemia, AR begins to convert glucose to sorbitol using the co-
factor NADPH (Aveleira 2009). Animal studies in diabetic rats 
demonstrate that the AR is present in the retina when the glucose 
concentration is high and has a significant role to play in DR 
pathogenesis (Balasubramanyam et al 2002).  Osmotic damage 
mediated by sorbitol leads to retinal capillary basement membrane 
thickening and the use of aldose reductase inhibitors (ARIs) can reduce 
the thickness of this membrane (Balasubramanyam et al 2002). One 
example of ARI is Sorbinil, which can minimize the swelling of small 
blood vessels in retina (Balasubramanyam et al 2002). There is a drug 
not tested in humans called ARI-809, which was used to prevent 
retinopathy in animals and it worked successfully (Ahmad 2013). 
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Figure 1: Polyol Pathway, this pathway induced oxidative stress during hyperglycemia. Sorbitol accumulates and produces osmatic 
stress, Adapted from Brownlee (2001) 
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1.3.1.2 Protein kinase C  
 
Protein kinase C (PKC) is another important biochemical-signalling 
pathway, whereby the activity of PKC increases in response to 
hyperglycemia. There are several cellular changes arising from PKC 
activation, with the most important being the increased permeability of 
the retinal vasculature and changes in blood flow to the retina 
(Alghadyan 2011). Another shift is neovascularisation, which arises 
when the basement membrane thickens causing ischemia, which in 
turn activates hypoxia inducible factor type 1 (HIF-1) (Alghadyan 
2011). HIF-1 increases the expression of VEGF (Alghadyan 2011). PKC 
is also involved in the stimulation of the expression of the VEGF gene 
which is also activated by HIF1 (Semeza et al 1998). The stimulation of 
PKC results when hyperglycemia enhances the production of 
diacylglycerol (DAG), which in turn stimulates PKC classic isoforms (α, 
β and δ) cofactors (as shown in Fig 2).  
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Figure 2: PKC Pathway, hyperglycemia induced PKC activity when the glucose metabolised to glycolytic intermediates via enhances the production of 
diacylglycerol (DAG), Adapted from Alghadyan (2011). Also, hyperglycemia increases advanced glycated end-products (AGEs), which in turn activates AGE receptors 
and cause the activation of DAG and PKC (Sandip 2009)
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PKC isoforms are divided into three groups; these groups are the 
classic group (cPKCs), the novel group (nPKCs) and the atypical group 
(aPKCs). The classic group includes cPKC-α, βI, βII, and γ and 
activation of this group needs phospholipid and calcium. The novel 
group includes nPKC-δ, ε, η, θ, and μ and activation of this group 
requires phospholipid only. The atypical group includes aPKC-ι, γ, and ξ 
and there is no requirement for calcium or phospholipid for activation 
(Donnelly et al 2004). PKC exists as a family of 15 isoforms 
(Fhearraigh) which acts as an important connection to the progression 
of DR (Lang 2007). Regulation of PKC isoforms occurs by generating 
DAG via activation and production of phosphoinositides and 
phosphatidic acid. In the case of hyperglycemia, DAG is generated via 
glyceraldehyde-3-phosphate (G3P), dihydroxyacetone phosphate 
(DHAP) and alpha-glycerol-phosphate (Lebovotz 2001). Lebovitz (2001) 
acknowledges that PKC phosphorylates serine and/or threonine kinase 
and this alters the intracellular function of a number of different 
proteins. The stimulation of PKC mediates neovascularisation and is 
vital in VEGF signalling, which has an important function in the initiation 
and progression of diabetes and DR (Lang 2007). While it has been 
demonstrated that high glucose concentration stimulates PKC via the 
Polyol pathway and reactive oxygen species (ROS) production, 
hyperglycaemia stimulates PKC-β, which is evident in tissues such as 
the retina. This activation is responsible for causing several changes 
such as the increased vascular permeability. Consequently, there exists 
compelling evidence to suggest that the PKC pathway is important in 
hyperglycaemia and DR because it stimulates NFκB, which in turn 
enhances the expression of pro-inflammatory genes (Brownlee 2005). 
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1.3.1.3 Advanced glycation end products 
 
Prolonged hyperglycemia can cause the formation of advanced glycated 
end-products (AGEs) when hyperglycaemia stimulates non-enzymatic 
glycation of proteins. AGEs work via cell receptors, which lead to 
oxidative stress and cause further diabetic complications (Sandip 
2009).  AGE products are formed by one of two pathways that impact 
upon vascular effects, namely receptor-independent and receptor-
dependent pathways. Oxidative stress and NFκB activation result from 
interaction of AGEs with their receptors (AGE-R1, AGE-R2 and AGE-R3). 
Extant literature demonstrates that vascular endothelial damage; 
microaneurysm formation and dysfunction of vasculature are related to 
aggregation of AGEs in the retina of diabetic patients and animals 
(Aveleira 2009). AGEs operating via cell surface receptors can be 
formed from prolonged hyperglycemia, which in turn cause cellular 
dysfunction and diabetic complications. The main targets for AGE 
toxicity are the retinal capillaries, which may lead to the apoptosis of 
pericytes. In addition, it has been shown that AGEs stimulate NFκB 
directly in vascular smooth muscle cells (VSMCs), resulting in cell 
damage (Patel & Santani 2009).  
 
1.3.1.4. Oxidative stress  
 
Oxidative stress due to the formation of ROS is directly associated with 
the progression of vascular complications of diabetes (Aveleira 2009). 
The production of ROS increases in hyperglycemia, causing activation of 
PKC and polyol pathways, as well as the production of AGEs. Indeed, 
vascular damage and lipid peroxidation are known to result from the 
formation of ROS, nitric oxide and hydrogen peroxide. The retina has a 
high glucose and oxygen absorption capacity and contains 
polyunsaturated fatty acids, with available literature demonstrating that 
it is these characteristics that expose the retina to damage related to 
oxidative stress. Elevated levels of oxidative stress markers, such as 
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thiobarbituric acid-reactive substances (TBARS), have been observed in 
the diabetic rat (Aveleira 2009). Moreover, hyperglycemia leads to 
increased oxidative stress, which in turn produces an elevated level of 
isoprostanes and prostanoids (Balasubramanyam et al 2002). Then, 
thromboxane prostanoid receptors are activated, which are found on 
the walls of blood vessels and in platelets. The activation of 
thromboxane prostanoid receptors causes inflammation and damage in 
the circulatory system. During hyperglycemia, the oxidative stress 
pathway causes an excessive production of superoxide, which is in turn 
connected to biochemical pathways such as the production of ROS 
involved in diabetic retinopathy. Consequently, oxidative stress 
resulting from hyperglycemia may be one of the main reasons for the 
excessive production of superoxides through the mitochondrial electron 
transport chain (ETC) (Balasubramanyam et al 2002). Excessive 
production of superoxide anion, according to Balasubramanyam (2002), 
initiates ROS and oxidative stress in diabetes. 
Studies in rats show increased levels of superoxide in cells of the retina 
that were incubated in high glucose and H2O2 (Tarr et al. 2013). In 
addition, VEGF is a growth factor that is associated with DR. There are 
two pathways, a calcium influx channel and a mitogen activating 
protein kinase signaling pathway are induced when VEGF binds to the 
membrane receptors. This activation causes a breakdown of the retinal 
barrier and leakage of vascular products. Therefore, anti-VEGF agents, 
such as ranibizumab and bevacizumab, can be used for the treatment 
of complications of DR (Tarr et al. 2013). 
 
1.3.1.5 Hexosamine pathway activation 
 
During glycolysis, glucose is converted into glucose-6-phosphate, which 
is converted to fructose-6-phosphate. The hexosamine pathway is 
initiated when glutamine fructose-6-phosphate amidotransferase 
(GFAT) converts fructose-6-phosphate into N-acetylglucosamine-6-
phosphate, precipitating a downstream reaction whereby N-
acetylglucosamine-6-phosphate metabolizes into uridine diphosphate 
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(UDP)-N-acetylglucosamine (UDP-GlcNAc) (as shown in Fig 3) (Aveleira 
2009). Furthermore, in hyperglycemia, the flow of glucose via the 
hexosamine pathway increases, resulting in insulin resistance (Aveleira 
2009). Researches have shown that the activity of GFAT is enhanced in 
T2DM and the expression of GFAT also changes in DR 
(Balasubramanyam et al 2002). This study further assumes that the 
GFAT is found in the tissues that are critical to the progression of 
diabetic complications; however, to date no evidence exists to show the 
presence of GFAT in eye tissues. It is suggested in the literature that 
high glucose concentration stimulates the hexosamine pathway, which 
in turn causes several shifts in protein function and/or gene expression, 
leading to progression of pathogenesis of diabetes complications 
(Balasubramanyam et al 2002). 
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Figure 3: Hexosamine Pathway, hyperglycemia increases the flux of fructose-6-phosphate into hexosamine Pathway. GFAT converts 
fructose 6-phosphate to glucosamine 6-phosphate, adapted from Alghadyan (2011)
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1.4 Nuclear factor kappa B 
 
1.4.1 The relationship between NFκB and diabetes 
 
NFĸB is a transcription factor, which plays an intrinsically important role 
in the regulation of different genes and proteins in the inflammatory 
response, including cytokines such as Tumor Necrosis Factor-α (TNFα) 
and Interleukin-1β (IL-1) (Chakrabarti 2007). NFκB consists of five 
polypeptide subunits including p50, p52, RelA (p65), C-Rel and RelB. It 
is also regulated by inhibitors that include IkB, IKB, IKB and Bcl-3 
(Figure 4) (Chakrabarti 2007). 
 
 
 Figure 4: Human NFκB1 Structure, Adapted from Chen 2014 
 
NFĸB1 gene produces a protein consisting of 968 amino acids with 
molecular weight of 105 KD. In the N-terminal region, which contains 
serine residues and Rel homology domain (RHD). RHD has 300 amino 
acids that important for DNA binding and interaction with IĸB proteins. 
The C-terminal has ankyrin repeats are found in the IĸB family 
members including IkBa, IkBb and IkBe (Chen 2014). GRR is a glycine-rich 
region, which is in the region 375 to 400 of NFKB, and it is important 
for guiding the NFĸB1 cleavage. 
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Whereas, various copies of ankyrin repeats are located in the C-
terminal region and it can be found in IB family members 
Phosphorylation occurs at Ser-903 and Ser-907 primers p105 and this 
is in response to TNF-α activation (GeneCards 2013).  
There are some studies that show that during ubiquitination of the 
proteasome, NFĸB1 is cleaved to make the p50 molecule. Additional 
studies proposed by Lin (1998) and Ghosh (Sankar et al. 1998) show 
that the glycine-rich region (GRR) is important to guide cleavage of 
NFĸB1 (Chen 2014).  
Through acting via nuclear localisation sequences (NLSc), IκB proteins 
can retain NFĸB dimers in the cytoplasm (Patel & Santani 2009). By IκB 
kinase (IKK) complex, the phosphorylation of cytoplasmic IkB begins, 
leading to activation of NFĸB. The NFĸB heterodimers discharge to the 
nucleus after degradation of IĸB through proteosomal system. Subsets 
of genes are stimulated due to binding of NFĸB heterodimers to nuclear 
DNA (Chakrabarti 2007).  
NFĸB is induced when free fatty acids bind to TLRs.  This activation 
causes insulin receptor substrate-l (IRS-l) phosphorylation via JNK and 
PKC. This change can lead to a down regulation of glucose transporter 
GluT-4 and leads to insulin resistance (Paneni et al. 2013).  
There are two activation pathways for NFĸB, namely the classical 
pathway and the alternative activation pathway (Figure 5). In the 
classical signalling pathway, phosphorylation of IĸB proteins occurs 
through and initiated by IĸB kinase (IKK) complex, causing 
polyubiquitination at sites of IKBα, which then leads to degradation 
through 26S proteasome. Afterwards, free NFĸB dimers discharge. The 
important component for signalling through the classical pathway is 
IKKβ. The classical pathway is also activated through binding of a 
ligand to the B-cell receptor (BCR), T-cell receptor (TCR) or toll-like 
receptor. Through this pathway, transcription of the target genes 
occurs which encode cytokines, chemokines and adhesion molecules 
(Nishikori 2005) all of which have been implicated in DR. The 
alternative pathway, NIK, which is also known as NFĸB inducing kinase, 
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stimulates IKKα homodimer (IKKβ and IKKγ) and leads to 
phosphorylation of p52 at two C-terminal sites through IKKα 
homodimer. Afterwards, ubiquitination and degradation causes the 
release of p52 (Nishikori 2005). Extant literature demonstrates that this 
pathway is activated through stimulation of TNF receptor, the receptor 
lymphotoxin-β receptor (LTβR) and B-cell activating factor, including 
CD40 and CD30 (Nishikori 2005). The stimulation of this pathway is 
responsible for controlling the adaptive immune system and lymphoid 
organ development (Nishikori 2005). In addition, activated NFκB 
complex binds to DNA at κB binding motifs like 5’-GGGRNNYYCC-3’ 
where R is Adenine (A) or Guanine (G) and Y is a Cytosine (C) or 
Thymine (T). Phosphorylated IKB generated from NFκB/IKB complex in 
turn lets NFκB molecules translocate into the nucleus (Romzova et al. 
2006). Then, transcription is stimulated through binding NFκB 
molecules with the consensus sequence (5’-GGG-ACTTTCC-3’) of 
several genes (Romzova et al. 2006). 
NFκB1 and NFκB2 known as large precursors, which are p105 and 
p100. These large precursors can generate the mature NFκB subunits 
p50 and p52. NFκB1 (p105) is cleaved to make the p50 during the 
ubiquitination process (Patel & Santani 2009). P52 is generated from 
p100. P50 and p52 as homodimers work as transcriptional repressors 
when they bind to κB elements. In addition, NFκB has two subunits that 
can exist as homodimers (p50/p50) or heterodimers (p65/p50). 
Homodimeric complex created by two identical molecules and a 
heterodimeric complex created by two different macromolecules. The 
Rel-like domain, which containing proteins that consist of homodimer 
and heterodimer set up from at least five subunit such as RelA/p65, 
RelB, NFκB1/p50, c-Rel and NFκB2/p52. Each subunit has various 
characteristic of DNA binding. For instance, the p50 homodimer is 
responsible for repression of gene transcription. Whereas, the p65/p50 
heterodimer is recognized as an activator of gene transcription (Patel & 
Santani 2009). The heterodimers RelB/p52 and p50/p65 are 
transcriptional activators of the NFκB gene that promotes gene 
transcription via binding to κB DNA. Binding of homodimers of the p50 
or p52 inhibits the transcription of the NFκB gene. RelA (p65)/p50 is 
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found in the classical pathway when activated by TNF-α and IL-1. 
Degradation of p100 forms the active p52 and it is available during the 
alternative pathway. NFκB-inducing kinase (NIK) activation of IKKα, 
results in the phosphorylation and processing of p100 and the 
formation of p52/RelB (Patel & Santani 2009).  
Evidence from the literature demonstrates that there is a central role 
played by NFĸB in the retina.  Patel and Santani (2009) state that 
“…retinal NFĸB is activated early in diabetes and remains activated for 
up to 14 months.” It was noted that diabetes has important effects on 
NFĸB, which leads to the movement of p65 subunits and p50 subunits 
to the nucleus of retinal pericytes and to the nucleus of retinal 
endothelial cells, respectively (Chakrabarti 2007). The expression of 
pro-inflammatory factors including cytokines such as TNFα are also 
regulated through stimulation of NFκB, resulting in elevated levels of 
other cytokines, for example IL-1, IL-6 and IL-8.  
In the case of DR, AGEs are irrevocably generated and they accumulate 
within the retinal capillary cells, with academics and medical 
practitioners postulating that more ROS are generated via the AGE 
pathway to cause the activation of NFκB and eventually cause further 
damage to the cells (Patel & Santani 2009). Consequently, patients 
with proliferative diabetic retinopathy and also diabetic rats have 
elevated levels of cytokines in their vitreous fluid (Nehme & Edelman 
2008). Extant literature also demonstrates that “…the levels of IL-1 
are also substantially increased in retinal capillary cells incubated in 
high glucose media” (Patel & Santani 2009).   
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Figure 5: Classical and Alternative Pathways of NFκB, adapted from Patel and Santani (2009) 
 
Figure 5 illustrates both the classical and alternative signaling pathways of NFκB activation: (Classical) external signals such as TNF-α, 
IL-1, B-cell and T-cell receptor stimulate the classical pathway and the phosphorylation of IKβα, resulting in the degradation of Ikβα by 
proteasome. These reactions encourage translocation of p50: RelA to the cytoplasm, the alternative pathway involves NIK activation of 
IKKα, resulting in the phosphorylation and processing of p100 and the generation of p52: RelB heterodimers (Patel & Santani 2009).
34 
 
 
Experiments have shown that activated NFĸB found in the retina 
following exposure to high glucose concentration causes movement of 
p65 into the nuclei of pericytes, endothelial cells and ganglion cells 
(Zhang et al 2011; Rohilla et al 2012). Indeed, one particular 
experiment conducted using the DNA binding technique demonstrated 
that NFκB DNA binding activity increased in endothelial or pericyte cells 
of the retina (Zhang et al 2011; Rohilla et al 2012). Evidence from 
mRNA and immunohistochemical analysis showed that the expression 
of NFκB increased in epiretinal membranes of diabetic retinopathy 
patients (Zhang et al 2011; Rohilla et al 2012). Moreover, single 
nucleotide polymorphisms (SNPs) were identified which were thought to 
have a role in diabetes (Ensemble, 2013). Therefore, polymorphisms 
were investigated in this study, using a bioinformatics approach 
through computational analysis. 
HIF1 is another important transcription factor that is controlled by 
hyperglycemia. There are several studies showing that, HIF1α level is 
decreased in diabetic patients cells and in cells that are cultured in high 
glucose medium (25mM) (Gao et al. 2007). During glycolysis, HIF1 
controls the enzymes that are required during this process and, which 
can moderate cellular glucose uptake (Xiao et al. 2013). The main role 
of HIF1 is the sensing of low oxygen levels in the cell. It is composed of 
two subunits: HIF1α  which is stabilised by O2 insufficiency and is 
continually expressed HIF 1 beta (Semenza 2001). In addition, HIF1α 
has been shown to be mediated in high glucose concentrations (Catrina 
et al. 2004).  
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1.5 Rationale for study  
 
The research in this project was carried out to investigate genetic 
polymorphisms within the NFĸB1 gene. Also, to examine the role of this 
specific inflammatory mediator in the progression of diabetes using the 
response of U937 cells to different glucose concentrations and H2O2. 
The initial approach of this study was to investigate NFκB as it has a 
prominent role in diabetes and in particular DR.  Bioinformatics was 
used to determine SNPs by analysing the genetic background of 
patients with diabetes. It has been shown that there is a connection 
between the polymorphisms of NFκB1 promoter regions and diabetes 
(Song et al. 2011). Therefore, this study screened SNPs within the 
NFκB1 gene locus and chose relevant SNP sites. 
Investigation of genetic polymorphisms is an approach, which can be 
used to study rare variants within a gene, and was used in this study. 
Some SNPs have several effects and induce several changes to occur. 
In addition, some of the SNPs, which are located in coding regions, can 
damage the protein structure and overall size and, thus, alter protein 
function. This alteration also can effect protein expression (Tadhg, 
2006). Also, promoter activity can be affected when SNPs occurred in 
5` regions. SNPs in 3`(UTR) regions can influence mRNA stability. 
Therefore, SNPs can lead to the alteration of gene function and can 
affect a transcript. The alteration of gene expression may lead to 
disease. Additionally, repeat polymorphisms that are located in 5`of 
human insulin gene can cause diabetes (Tadhg, 2006).  
In order to identify a SNP of interest the first part of this study uses 
bioinformatic search protocols. The second part of this study was to 
investigate the SNP of interest using specific restriction enzymes. 
Finally, the effect of NFκB and HIF1α mRNA expression in response to 
different glucose was also carried out in response to oxidative stress. 
The finding of this study is highlighted as novel, as no one has 
examined the gene databases to identify the SNP rs230539 in NFκB 
before in U937 cells.   
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Chapter 2: 
Materials and Methods 
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2.1. Materials  
 
All chemicals were purchased from Sigma-Aldrich, UK and all cell 
culture reagents were obtained from Gibco, UK unless otherwise 
specified. 
The human U937 cell line used in this study was purchased from the  
European Collection of Cell Cultures (Cat no. 85011440, ECACC, Public 
Health England, UK).  U937 cells were derived from malignant cells of a 
pleural effusion from a 37-year-old Caucasian male with a diffuse 
histolytic lymphoma, which expresses many monocytic-like 
characteristics.  U937 cells are a good experimental tool for use in the 
examination of monocytic cell function. The U937 cells were pre- 
differentiated cells. 
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2.2. Methods 
 
2.2.1 Bioinformatics 
 
A range of in silico analysis tools were used to explore the current 
genetic information available regarding the human NFĸB1 gene.  The 
websites used for the bioinformatics analysis in this study are listed in 
Table 1.  
 
Table 1: Bioinformatics websites used for in silico analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Websites used to explore genetic information of human NFĸB1 gene and for the 
identification of sequences of human NFKB1 gene, the design of primer sequences, the 
identification of potential phosphorylation sites and the location of restriction sites 
within the amplified sequence. 
 
 
Name of bioinformatics analysis Website URL a 
The Ensemble genome browser http://www.ensembl.org 
National Centre for Biotechnology 
Information (NCBI) 
http://www.ncbi.nlm.nih.gov/snp 
Primer Quest http://eu.idtdna.com/PrimerQuest/
Home 
NetPhos 2.0 http://www.cbs.dtu.dk/services/ 
NetPhos/ 
Nebcutter http://tools.neb.com/NEBcutter2/ 
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The Ensemble genome browser is a collection of genome databases for 
vertebrates and other species whilst, the National Centre for 
Biotechnology Information (NCBI) (National Center for Biotechnology 
Information. 2012) provides access to biomedical and genomic 
information.  These resources were used to identify the sequence of the 
human NFĸB1 gene, to locate highly conserved regions within the gene 
and to review known NFĸB1 sequence variants that may be linked with 
diseases, such as, diabetes. Primer Quest (Primer quest. 2013) 
programme is a tool used for designing primers for PCR and 
sequencing. The programme NetPhos was used to identify the 
phosphorylation sites and to show predictions for serine, threonine and 
tyrosine phosphorylation sites for proteins.  Nebcutter tool (Vincze et 
al. 2014) was used to determine the sites of restriction enzymes 
through providing a DNA sequence analysis.  
Ensemble (2013) was used as follows: The species was selected as 
‘Human’ and then the name of the gene ‘NFĸB1’ was typed into the 
search bar.  The search was started by clicking on the ‘Go’ button 
followed by ‘Gene’ which reveals a variety of information about the 
gene including, gene ID, genomic location, transcripts and sequence 
variations. Also, the Ensemble website provides an option for a ‘Map 
view’, which shows chromosomal diagrams and single nucleotide 
polymorphism (SNPs). In addition, the gene region display provides the 
intronic and exonic regions and the untranslated regions (UTR) in 
relation to the position of a SNP. The genetic information can be 
created in a graphical display format, which presents mapping of the 
SNPs over the genetic sequence. 
As an alternate presentation the format of the sequence was also 
converted to a text based format (FASTA) and the programme NetPhos 
2.0, was used to identify phosphorylation sites to determine potential 
protein regulatory sites associated with SNPs. NetPhos was used as 
follows: 
The sequence in FASTA format was pasted into the input field and 
“submit the job” was selected. Then, the programme ran and displayed 
the output in the browser window.  
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NCBI was used to obtain the FASTA sequence which is the text based 
format used to represent a nucleotide sequence that could then be used 
with Ensemble to calculate protein function prediction via Sorting 
Intolerant From Tolerant software (SIFT) and Polymorphism 
Phenotyping tool (PolyPhen- V2). SIFT shows the effect of an amino 
acid replacement on protein function which depends on the amino acid 
physical properties and sequence homology. Polymorphism Phenotyping 
(PolyPhen) is a tool, which can be used to show the effect of an 
exchange of nucleotides on the structure and function of human 
proteins. Therefore, predicting the impact of the SNP on protein 
function and structure can be calculated by using these tools. The 
calculation was preceded by providing a score and a qualitative 
prediction (probably damaging, possibly damaging, or unknown).  
Using the Ensemble programme, a specific SNP of interest was 
identified for further study.  The region of interest was then analysed 
using the programme Primer Quest (Primer quest. 2013) to generate 
specific primers that would span the identified region of interest.  This 
was followed by a BLAST ran of the sequences selected to ensure 
specificity of the DNA regions. New England Biocutter programme was 
then used to identify restriction enzyme sequences within this region 
that could be used to further distinguish the SNP of interest. 
 
2.2.2 Cell culture and cell counting 
 
U937 cells were cultured in Roswell Park Memorial Institute (RPMI-
1640) medium with 2 mM L-glutamine, supplemented with 100 μg/mL 
streptomycin, 100 U/mL penicillin and 10% (v/v) heat inactivated foetal 
bovine serum (FBS). The cell suspension was centrifuged at 10,000 g 
(HERA Cell 150, Heraeus/Thermo Fisher Scientific/Kendro, UK) for 5 
minutes. After centrifugation, the supernatant was removed and the 
pellet resuspended in 1 mL RPMI medium. The cells were counted using 
a Neubeur haemocytometer and 1 million cells transferred to a T-25 
(25 cm2) culture flask with 5 mL RPMI medium. The cultured cells were 
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incubated in an incubator at 37°C, with 5% CO2 (HERA Cell 150, 
Heraeus/Thermo Fisher Scientific/Kendro, UK).  After four days, U937 
cells were counted and transferred to a 6 well plate (1 × 104 cells/well) 
for experiments as detailed below.  
In brief, a 50-μL aliquot of cell suspension was gently mixed with 0.4% 
(v/v) of Trypan blue dye (1:1 dilution) and added to the 
haemocytometer.  Trypan blue was used to visualise viable and non-
viable cells, which appear clear and blue, respectively. Non-viable cells 
appear blue because of the increased permeability of the plasma 
membrane. The cells were viewed under a microscope at 100x 
magnification (Leica, Leica Microsystems, UK) and the number of cells 
in the outside four squares counted. The cell number was determined 
using Equation 1. 
Equation 1:  
Number of cells/ml= number of cells counted × dilution factor × 104 
After counting, the cells were seeded and grown in 6-well plates. 
Multiple plates were used to allow for the incubation of U937 cells at 
the following time intervals: 0, 30, 60 and 180 minutes, with and 
without hydrogen peroxide (H2O210 μM) at 37°C, with 5% CO2. In 
addition, 1x107 U937 cells were grown in different glucose 
concentrations (5.5 mM, 20 mM and 40 mM) and incubated for 24 
hours at 37°C, with 5% CO2.  
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2.2.3 DNA extraction and purification 
 
DNA extraction was carried out using the PeqLab mini kit according to 
the manufacturer’s instructions (peqGOLD Tissue DNA Mini Kit, 
PEQLAB_v0912, PeqLab, UK). Proteinase K (25 mg) and RNase A (10 
mg) were provided as powders and were dissolved, before use, by 
vortexing in TE (Tris EDTA (Ethylenediaminetetraacetic acid)) buffer (10 
mM Tris, pH 8.0, 1 mM EDTA). For Proteinase K, 1.25 mL TE buffer was 
added to 25 mg to give a final concentration of 20 μg/μL and was 
stored at -20 °C in 50 μL aliquots, until required. For RNase A, 500 μL 
TE buffer was added to 10 mg to give a final concentration of 20 μg/μL. 
The RNase A solution was then stored in 50 μL aliquots at 4oC, until 
required.  
Cells grown in 6 well plates were collected and centrifuged. After 
centrifugation, the cells were retained and the supernatant was 
discarded. DNA lysis buffer (400 µL) was added to the U937 cell pellet 
and mixed by pipetting up and down. Proteinase K (20 µL) was firstly 
added to cells, the contents of the tube was gently mixed, then 15 μL 
RNase A was added and the contents of the tube mixed again by 
pipetting up and down. The samples were incubated at 50°C for 30 
minutes and mixed 4 times during the incubation by vortexing for 10 
seconds. After incubation, 200 μL DNA binding buffer (which contains a 
chaotropic salt) was added and mixed by pipetting and vortexing. A 
Perfectbind DNA column was placed in a collection tube and the sample 
(750 µL) loaded onto the column. The Perfectbind DNA column with the 
collection tube was centrifuged (Eppendorf 5415 D centrifuges, UK) for 
1 minute at 10,000 g. The column was kept and the flow-through was 
discarded. DNA Wash buffer (650 µL) was added to the column and 
centrifuged for 1 minute at 10,000 g. The flow-through was discarded 
and the washing step was repeated three times. After the flow-through 
was discarded for the third time, a new collection tube was used and 
centrifuged for 2 minutes at 10,000 g (thus, this was the drying step). 
Then, Elution buffer (200 μL; 10 mM Tris-HCl, pH 9.0) was added to the 
column and incubated for 3 minutes at 70oC. Then, the sample was 
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centrifuged for 1 minute at 6,000 g (thus, this was the elution step). 
The eluent contained the DNA so this tube was not discarded.  
Finally, genomic DNA was collected in an Eppendorf tube (100 µL+ 100 
µL = 200 μL total final volume). DNA concentration was measured by 
diluting the sample 1:10 and using a spectrophotometer (BioMate 5 
spectrophotometer, Thermo Scientific, USA) set at 260 nm and 280 nm. 
The 260/280 nm ratio was determined and the final concentration of 
DNA recorded since the amount of UV absorbed by the DNA solution at 
260 nm is directly proportional to the amount of DNA in the sample 
where a optical density unit of 1 is equal to 50 µg/mL DNA.  The 
concentration of DNA in each sample was determined using Equation 2. 
 
Equation 2:  
Concentration (μg/mL) = (A260 reading) × dilution factor × 50 μg/mL 
 
 
2.2.4 Polymerase chain reaction (PCR) 
 
The SNP of interest was selected and amplification of the region of DNA 
containing the selected SNP was carried out using genomic DNA (gDNA) 
from U937 cells.  The amplification was carried out with specific primers 
Table 2). That would generate a product of 206bp. 
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Table 2: NFĸB Forward and Reverse Primers used in PCR. 
 
 
 
 
 
Master mix (25 µL) contained RedTaq, 0.2 μM Forward Primer, 0.2 μM 
reverse primer and H2O. The samples were placed in a thermocycler 
(Biometra T3000 thermocycler, Germany) with cycling conditions as 
follows: denaturation at 94C for 1 minute, annealing at 56oC for 2 
minutes and elongation at 72oC for 3 minutes (for a total of 30 cycles).  
 
2.2.5 Gel electrophoresis  
 
Agarose gel electrophoresis was used to determine the size of DNA 
fragments and for analysing amplified DNA bands. The gel was 
prepared using electrophoresis grade agarose (Invitrogen, Life 
Technologies, USA) at a concentration of 1.8% (w/v) in Tris-Borate-
EDTA buffer (1×TBE) procedure was followed according to the 
manufacturers’ protocol. Agarose was measured (0.99 g) and 1xTBE 
buffer (55 mL) added. The mixture was heated using a microwave for 1 
min until the solution appeared clear and without bubbles. Then 2 μL of 
gel red nucleic acid stain was added, and gently mixed. The comb was 
placed into the gel mold on one end. The melted agarose mixture was 
poured into the gel mold. After the gel had cooled and solidified, the gel 
mold was inserted into the gel tank, covered with 1xTBE buffer and the 
comb removed which left empty wells for addition of the samples. 
Samples (5 μL) of the amplified DNA and fragments of known sizes 
(HyperLadder 100bp, Bioline, UK) were loaded onto the gel and 
 Length 
of 
primer 
Tm  
(Melting 
Temperature
, °C)  
GC % (Self 
Complementarit
y)  
Seq (Primer Sequence, 5'->3')  
Forward  24  62  45.8  CAGAGAGACCAGAGAAACCTTTAC  
(Sense)  
Reverse  22  62  45.5  
 
GAGTGCTGTGTGTGAGGAAATA  
(antisense) 
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electrophoresis ran at 80V for 1 hour. DNA fragments were then 
visualised using the Fusion X7 (Peqlab, UK) and an image of the gel 
retained. DNA fragment sizes were then determined by comparison 
with the distance migrated by DNA of known size.  The distance 
migration was measured via using a ruler. A table for each gel was 
created, which contained the ladder fragments (bp), the fragment log 
(log 10 base pairs) and the migrated distance (in cm). Then, excel was 
used to create a scatter graph. The fragment log was plotted on the y 
axis and the migrated distance plotted on the x axis. Next, a straight 
line was created and the equation of the straight line used to determine 
the size of the DNA fragments.  
 
2.2.6 Restriction digest 
 
Digestion of the PCR products was done using specific restriction 
endonucleases. The New England Biolabs (NEB) cutter software V2.0 
(Table 1) was used to find specific restriction enzymes to digest 
rs230539 sequence as shown in Figure 6. 
 
Figure 6:Restriction Enzymes (adapted from Vincze et al., 2014) which can be 
used to digest PCR products for a region of 206 bp of rs230539. 
 (a) A region of 206 bp of rs230539 was analysed for specific restriction 
enzyme sites using NEB cutter software. The two sites identified are for (b) 
HpyCH4III and (c) Alu1. 
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A number of enzymes were found to cut the DNA sequence of the PCR 
product.  The enzyme HpyCH4III (TaaI) was found to cleave at the SNP 
site generating products of 133 bp and Alu1 restriction enzyme cleaves 
the PCR product at position 175 predicting that 2 fragments of 175 bp 
and 31 bp should be visible.  
PCR products were digested by the enzyme HpyCH4III (New England 
BioLabs, UK), for one hour, 4 hours or overnight at 37oC. This enzyme 
should cleave the AC N GT site and the fragment length was analysed 
on a 1.8 % (w/v) agarose gel (prepared as described in Section 2.2.5). 
Digestion of rs230539 region was carried out in a total volume of 20 
μL: using 5 μL of PCR product with 1 μL endonuclease HpyCH4III (refer 
to Table 3 for details). In addition, two other restriction enzymes Alu1 
and PvuII (New England BioLabs, UK) were tested for digestion of 
rs230539 region. Digestion was carried out in a total volume of 20μL as 
mentioned in Table 3. Samples were incubated at 37° C for 1 hour and 
resolved using agarose gel electrophoresis as previously outlined in 
Section 2.2.5. 
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Table 3: Samples prepared for digestion (5 sample, un cut, with Hpych4iii, 
with AluI and with PvuII) 
Sample No. PCR reagent Enzyme Buffer Water (total 20 
µl) 
1 (-ve)  5 µl - 2 µl (cutsmart, 
100 buffer) 
13 µl 
2 5 µl 1 µl ( of 
Hpych4iii) 
2 µl (cutsmart, 
100 buffer) 
12 µl 
3 5 µl 1 µl ( of Alu1) 2 µl (cutsmart, 
100 buffer) 
12 µl 
4 (-ve) 5 µl - 2 µl ( of 3.1 
buffer) 
13 µl 
5 5 µl 1 µl ( of PvuII) 2 µl ( of 3.1 
buffer) 
12 µl 
 
 
2.2.7 PCR purification  
 
The Qiagen MinElute Reaction Cleanup Kit (Qiagen, UK) was used to 
purify the amplified DNA from enzymes, salts and primers. The protocol 
was carried out according to the manufacturers’ procedure. Briefly, 5 
volumes of Buffer PB (binding buffer, 5 M Gu-HCl and 30% isopropanol) 
to 1 volume of the PCR sample were added together, therefore, 225 μL 
of Buffer PB was added to 45 μL of of PCR sample (with primer 
concentration, 0.2μM). The colour of the mixture was violet, therefore 
10 μL of sodium acetate, pH 5.0 was added to turn the colour of the 
mixture to a yellow colour and procedure was followed according to the 
manufacturers’ protocol. QIAquick spin column was placed in a 2 mL 
collection tube. The sample was applied to the QIAquick column and 
centrifuged (Eppendorf 5415 D centrifuge, UK) for 30 seconds at 
17,900 g.  Flow-through was discarded and the QIAquick column was 
placed back into the tube. Buffer PE (0.75 mL) was added (according to 
the manufacturers’ procedure) to the QIAquick column and centrifuged 
at 17,900 g for 30 seconds. Flow-through was discarded and QIAquick 
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column was placed back into the tube. The column was centrifuged at 
17,900 g for one minute and transferred to a clean 1.5 mL centrifuge 
tube. Buffer EB (50 μL) (10 mM Tris·Cl, pH 8.5) was added to the 
membrane of the QIAquick column and centrifuged at 17,900 g for 1 
minute.  
 
2.2.8 Sequencing 
 
DNA samples and primers were sent to the College of Life Sciences, 
University of Dundee, UK, for sequencing. Primer concentration 
required to be sent for sequencing was 3.2 µM along with 20 ng PCR 
product. The similarity between two sequences was done via comparing 
the predicted sequence and the sequence of the PCR product. 
 
2.3 RNA extraction and purification 
 
2.3.1 RNA extraction using RNeasy mini kit  
 
U937 cells were incubated in six well plates (maximum of 107 cells per 
well). Cells were collected in individual Eppendorf tubes and centrifuged 
at 10,000 g (Eppendorf 5415 D centrifuge, UK) for 15 minutes (at 4oC). 
The supernatant was removed from each tube and the cell pellet stored 
on ice until all samples were collected. Ice cold Phosphate Buffered 
Saline (PBS) (1 mL) was added to the cell pellet and the cells were 
gently resuspended, and re-centrifuged at 10,000 g for 10 minutes. 
The supernatant was removed and discarded. This washing step was 
repeated three times and the supernatant removed after each wash. 
RNALater (Invitrogen, UK) (1 mL) was added to the cell pellet. 
RNALater is an RNA stabilisation solution used to stabilise and keep 
RNA in an intact form. The sample was gently pipetted up and down to 
ensure all cells within the pellet were exposed to RNALater. All samples 
were stored at -20°C, until required. 
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RNA was extracted by using the RNeasy mini kit (Qiagen, UK, Cat No 
74104). The methodology for RNA extraction was followed as stated in 
the manufacturer’s protocol. Briefly, a 300 μL aliquot of 70% (v/v) 
ethanol was added to the cell pellet and mixed by pipetting. The 
homogenised sample (500 µL), including any precipitate, which was 
formed on addition of ethanol, was added to an RNeasy spin column 
which was placed in a 2 mL collection tube. The tubes were centrifuged 
(Eppendorf 5415 D centrifuge, UK) at 8,000 g for 15 seconds to bind 
the RNA onto the column and the flow-through discarded after 
centrifugation. Washing buffer (RW1; 750 μL) was added to the spin 
column and centrifuged at 8,000g for 15 seconds. Ethanol was added 
(44 mL of ethanol added to obtain 55 mL RPE buffer) to the RPE buffer 
(concentrated wash buffer used for washing membrane bound RNA) 
and this was then added and centrifuged at 8,000 g for 15 seconds. 
The wash step was repeated by the addition of 500 μL RPE buffer and 
centrifuged at 8,000 g for 2 minutes. The flow-through was discarded 
each time. The column was then placed in a fresh 2 mL collection tube 
and centrifuged at 8,000 g for 1 minute to dry the columns from any 
carryover of RPE buffer. Finally, the spin column was placed in a 1.5 mL 
collection tube and 50 μL RNase free water (elution buffer) added 
directly on to the RNeasy membrane. The tubes were centrifuged at 
8,000 g for 1 minute to elute RNA. The samples were ready to be used 
immediately or stored at -20˚C until required. The concentration of 
RNA was measured by using a spectrophotometer at an absorbance of 
260 nm. The solution was diluted (1:20) in Diethylpyrocarbonate 
(DEPC) treated water.  
20 μL RNA + 380 μL DEPC dH2O  
The concentration was calculated using Equation 3:  
A260 x dilution factor x 40 = X μg/mL RNA concentration 
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2.3.2 RNA extraction using TRIzol reagent 
 
 
An alternate method of RNA extraction was also used. Total RNA was 
extracted from 1x107 U937 cells. U937 cells were homogenised in 1 mL 
TRIzol reagent (Sigma, UK) (which is a phenol-based solution) for 5 
minutes at room temperature (RT). Chloroform (200 µL; minimum 
grade 99%) was then added and the phases separated by 
centrifugation (PK121R centrifuge, ALC International, Italy) for 15 
minutes at 17,900 g at 4oC. The RNA (present in the upper phase) was 
transferred to a fresh Eppendorf tube and incubated with 500 μL of 
Isopropyl alcohol (propan-2-ol, Fisher Scientific, UK) at RT for 10 
minutes to allow for RNA precipitation. After centrifugation for 10 
minutes, at 12,000 g, the RNA pellet was washed with 500 μL of 75% 
(v/v) ethanol and then dissolved in 20 µL DEPC treated water. The 
concentration of RNA was measured by using a spectrophotometer at 
an absorbance of 260 nm (Table 4). 
 
Table 4: RNA concentration for 1x107 U937 cells for loading of 1μg and 2g of 
the sample  
 
 
 
 
 
 
 
Sample  RNA 
Concentration 
(µg/mL) 
RNA 
Concentration 
(µg/1000 µL) 
Volume of 
RNA (µL) 
Volume 
of H2O 
required 
(made 
up to up 
to 12 
µL) 
Volume 
of 
loading 
dye 
required 
(µL) 
107 
(sample1) 
(1 µg) 
2432 2.432 1/2.432= 
0.4 
9.6 2 
107 
(sample2) 
(2 µg) 
2432 2.432 2/2.432=0.8 9.4 2 
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2.4 cDNA synthesis and reverse 
transcriptase polymerase chain reaction 
(RT-PCR) 
 
RNA (4 µg) extracted using TRIzol reagent was reversed transcribed in 
a total volume of 20 µL, using Tetro cDNA synthesis kit (Bioline, UK) 
using oligo dTprimers and following the procedure according to the 
manufacturer’s instructions and ran on a Biometra thermocycler (T3000 
Thermocycler, Biometra, UK). All samples were incubated at 45oC for 
30 min, when using oligo dT primers. Then, the reaction was 
terminated by incubating at 85oC for 5 min, and chilled on ice. All 
samples were then stored at -20°C until required.  
 
Moreover, the PCR was run with 0.2 µM NFĸB and 0.2 µM HIF1α 
primers as follows: 
a. 94oC for 2 minute. 
b. 94oC for 50 Sec. 
c. 60oC for 1 minute. Annealing Tm  30 cycles 
d. 72oC for 2 minutes. 
e. 94oC for 50 sec. 
f. 60oC for 1 minute. 
g. 72oC for 2 minutes. 
h. 4oC. 
i. Transferred for storage at -20oC. 
 
These samples were analysed on a 1.8% (w/v) agarose gel ran at 80V 
for one hour.  
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Modified conditions were used with β2- microglobulin (1 µM) for a total 
of 25 cycles and was conducted as follow, 
a. 94oC for 4 minute. 
b. 94oC for 1 minute. 
c. 59oC for 2 minute. Annealing Tm  25 cycles 
d. 72oC for 2 minutes. 
e. 72oC for 8 minutes. 
f. 4oC. 
g. Transferred for storage to -20oC. 
 
 
The samples (5 µL) and ladder (2 µL) were run on a 1.8% gel, at 80 V 
for half an hour. 
cDNA was amplified using β2- microglobulin and β-Actin as internal 
controls, HIF1-α and NFĸB primers with Red TaqMan Universal PCR 
master mix (containing Redtaq, forward primer and reverse primer and 
H2O), PCR reagent (total 50μl) in primer concentration 0.2μM per 
primer. The details of the primers used are in Table 5. 
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Table 5: Details of primers used for PCR. The table illustrates the primers 
used for cDNA amplification, which are HIF1α, NFĸB, β-Actin and β2-
Microglobulin. HIF1α sized at 181bp, NFĸB sized at 199bp, β-Actin sized at 
387bp and β2-Microglobulin sized at 250bp. 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
a
m
e
 
Primer Produ
ct 
size 
(bp) 
Lengt
h 
Tm 
˚C 
%GC Acc.No 
H
IF
1
 
a
lp
h
a
 
F:5’ GTCTGAGGGGACAGGAGGAT-3’ 
R:5’ GAAAGGCAAGTCCAGAGGTG-3’ 
 
181bp 
20 
20 
64.5 
63.8 
60 
55 
U22431 
N
F
ĸ
B
 
F: 5'-CAGCCCCAGAAACAGCTGAT-3' 
R: 5'-ACCAGGTCCACCTCGATCTT-3' 
 
 
199bp 
20 
20 
53.8 
 
55 
55 
X61498 
B
e
ta
-A
c
ti
n
 
F: 5'-GACCCTTGCCCTCACTGCTTT-3' 
R: 5'-TTCAGGGGGACCTTGGTCAAT-
3' 
 
387bp 
21 
21 
68.6 57.1 
52.4 
NG008793 
B
e
ta
 2
- 
M
ic
ro
g
lo
b
u
li
n
 
F: 5'-GGCTATCCAGCGTACTCCAAA 
R: 5'-CGGCAGGCATACTCATCTTTTT-
3' 
250bp 21 
22 
71 
69 
52 
45 
NM004048 
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Chapter 3.  
Results 
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3.1 Bioinformatics output 
 
3.1.1 Detection of SNPs and identification of the 
NFĸB1 region 
 
The bioinformatics output showed that the genomic DNA encoding the 
NFκB p105 subunit is located on chromosome 4 (Figure 7). The protein 
has 968 amino acids and is 105356 Da in size.  
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Figure 7: Chromosome 4: 102,939,992-102,951,588, (Ensemble, 2013) and the position of NFĸB1 p105 located on chromosome 4.  
Red box and arrow show NFκB1 gene located on the q arm of chromosome 4 at position 24. 
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The NCBI programs were used to identify the region of interest and viewed 
under ‘Gene view’. The ‘in gene region’ showed the view of the exonic, 
intronic and untranslated regions near the SNPs, whilst under the ‘gene 
section’, the graphics view produced the mapping of the SNPs (Table 6). 
  
It was found that there are different classes of variant that may occur in 
the sequence. These variants can make a change and may have a 
consequence to the gene product and / or gene expression. Table 6 
describes the types of variant identified within the NFĸB gene. 
Consequently, changes may occur in chromosome structure or in a single 
base in the genetic sequence. Sometimes, these variations might not 
affect or be linked with a disease because the changes do not influence 
gene instruction and protein function. Changes in a single nucleotide can 
lead to disease. Changes in DNA nucleotide may affect protein function. 
This change may influence gene expression level, and may lead to 
changes in the biological process through changing RNA and protein 
regulation. 
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Table 6: Summary of NFκB1 variants (SNPs) identified in NFkB using Ensemble, 
2013 
 
 
 
 
 
 
 
 
 
 
 
 
Different types of variants were found in NFĸB1 (Table 6). Ensemble was 
then used to identify the NFĸB1 sequence variants that are linked with 
disease. Table 7 shows that there are different variations associated with 
several different diseases. 
  
 
 
 
 
 
 
 
 
Number of 
variant 
consequences 
Type of variant Description of variant 
85 Splice region 
variant 
A sequence variant in which a 
change has occurred within the 
region of the splice site, either 
within 1-3 bases of the exon or 3-8 
bases of the intron. 
88 Non coding 
exon variant  
A sequence variant that changes 
non-coding exon sequence. 
3 Splice donor 
variant 
A splice variant that changes the 2 
base regions at the 5' end of an 
intron. 
19 Splice 
acceptor 
variant 
A splice variant that changes the 2 
base regions at the 3' end of an 
intron. 
10306 Intron variant A transcript:  variant occurring 
within an intron. 
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Table 7: Variations of NFĸB1 in Humans associated with disease 
 
Variation ID 
 
Description 
 
Phenotype(s) 
rs230489 
 
A dbSNPa Variation Kidney function and endocrine traits-
GFRb 
rs230529 
 
A dbSNP Variation Schizophrenia (treatment refractory)  
rs230539 
 
A dbSNP Variation Type II Diabetes Mellitus 
rs7665090 
 
A dbSNP Variation Primary biliary cirrhosis 
rs2991716 
 
A dbSNP Variation Kidney function and endocrine traits-
CysCc 
adbSNP: The Single Nucleotide Polymorphism Database. bGFR: Glomerular 
filtration rate. cCysC: cCystatin-C. 
As detailed in Table 7, there are many different variants that are 
associated with many diseases such as, schizophrenia, primary biliary 
cirrhosis and T2DM. The rs230539 SNP was selected and it is located on 
Chromosome 4:103495532. This variant has been shown to be associated 
with T2DM (Ensemble, 2013). This means that there may be a relationship 
between T2DM and the polymorphisms of NFκB1. This SNP rs230539 
(A/G) is located within the intronic region of NFκB1 and this is shown in 
more detail in Table 8.  
Table 8: Details of variant rs230539 
 
 
  
 
 
Functional 
class 
Wild type 
nucleotide 
Variant 
nucleotide 
Chromosome 
strand 
orientation 
Chromosome 
variant 
position 
Intron A G Forward 103714569 
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The SNPs which mean a variation of the DNA sequence that happen in the 
genome when a single nucleotide – A, T, C or G (Ensemble, 2013). Table 8 
shows the variant of interest is rs230539 SNP, which is intronic variant. 
Rs230539 A/G genotype in the intron region of NFκB1. In addition, if the R 
is A it is a wild type nucleotide and if it is G it is a variant nucleotide. 
 
 
 
3.1.2 Impact of SNPs 
 
3.1.2.1 Identification of the phosphorylation site 
 
Identification of phosphorylation sites was conducted to find the 
phosphorylation site and also to determine if the variant was 
phosphorylated or not.  
NetPhos 2.0 was used to identify the phosphorylation sites, if any and the 
output are shown in Figure 8.   
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Figure 8: Sequence of interest, identified phosphorylation sites and predicted 
score, (Blom, N. et al.,2013).  
Figure 8 A, B and C illustrate the phosphorylation sites in the sequence. A, 
Sequence of interest for rs230539 was uploaded twice with represented by either 
A or G. B, Identified phosphorylation sites which shows the phosphorylation sites. 
C, Predicted phosphorylation sites which shows the predicted phosphorylation 
score for the sequence.  
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Figure 8 A shows the nucleotide sequence for the region of interest. 
DNA is transcribed to RNA, during transcription, introns removed and 
spliced out by spliceosomes leaving the exons to create the amino acid 
product via translation process. Sometimes, introns are not spliced out 
during transcription, resulting the intron retained within mRNA as a part of 
an exon. Phosphorylation has an important role in eukaryotic cells such as 
gene expression.  Some residues are not phosphorylated whether due to 
the residue not being Serine (S), Threonine (T), or Tyrosine (Y) and they 
are labelled as a dot or because the score is under the threshold. 'S', 'T', 
or 'Y’ these are being marked if the scores that are over the threshold of 
0.500, blue line (Figure 9 C) (Blom et al., 2013). The phosphorylation site 
in Tyr is one and 40 Thr phosphorylated sites programme predicts, Figure 
8B (Blom et al., 2013). 
The calculation was preceded by providing a score and a qualitative 
prediction (probably damaging, possibly damaging, or unknown). The data 
that is shown in the SIFT column is as a score of the qualitative prediction. 
For example, if the amino acid change with a score 0 is known as tolerated 
and mean the protein function is neutral, while the change of amino acid 
with a score < 0.05 are known as deleterious, which means harmful 
mutation and can affect protein function and cause disease. In the last 
column is a PolyPhen-2, which shows the impact of an amino acid change 
on the function and structure of protein via databases and tools such as 
the Define Secondary Structure of Proteins tool (DSSP). A prediction for 
each amino acid change with SIFT tool is calculated. Both score and 
qualitative prediction (one of 'probably damaging', 'possibly damaging', 
'benign' or 'unknown') are provided. Table 9 describes each score 
(Ensemble, 2013). 
  
 
 
63 
 
 
Table 9: Score and Qualitative Prediction, (Ensemble, 2013) 
 
Tool Score Qualitative prediction 
PolyPhen 0 Probably damaging 
PolyPhen 1 Possibly damaging 
PolyPhen 2 Benign 
PolyPhen 3 Unknown 
SIFT 0 Tolerated 
SIFT 1 Deleterious 
 
According to the results in Figure 8, SNP rs230539 is not phosphorylated. 
Therefore, PCR approach was selected to investigate rs230539 further.  
 
3.1.2.2 Primer design for PCR  
 
In order to investigate the SNP rs230539, primers were designed for PCR. 
The FASTA sequence for the region of interest where rs230539 from 
Ensembl website is located is shown in Figure 9 and the variant location is 
shown in red with the neighbouring (other) variants shown in blue. 
Primers have to be designed within the length 18-30 oligo nucleotides to 
allow a space for restriction enzyme cleavage.  
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TGTACTTGTGTACAAATTCTGTCTTCTGGATCTATTTTTGTTTAGTTTTTGTCCTAATTA 
TGAATTATATTTTTCTATTTCTTTCCATGCCTGTTAGTTTTTTATTGGATGACAGGTATT 
TTGAATTTTGTATCGTTAAGTCTTGGATTCCTTTTTTTTTTTTTTTTTTTGATGTGCTTT 
TAAATACGTTTGAGGATTGGGATRAAGTTAAATTTGGGAACAGTTTGATTTTTTTGATTC 
TTTCTAAACTTACTTTTAAGCTTTATCAGAGAGACCAGAGAAACCTTTACTCTAGGGTTA 
ATTTGACATCATTGCTAAGGCAGTACCTTTCTGAATTTTCAACCTGATGCTCCATGTATT 
ACAAGATTTCTTGAACTATTCCAGCCCCATATGTGTTACARTAATTTTTCTGCCTCCACC 
TCTGTGGTGGTTCTTTTCCCAGCTTTGACATATTTCCTCACACACAGCACTCAGCTGAAG 
ACTCCAGTGAYCTCTGAGTGTAYCTCTGTTTGCGGTTTCTTCCTTTCCGGTACTCTGCTT 
GTGAGTTTTAGCCTCYTTGGCTTCCTCCAATATTTAACTGTGTCTCSTCAACCTCAGAGA 
TTGCCAGGCTCTGTTGGGGTTCCTCCTTCCTGTGCTGCAGCCTGGGACTCTTTAGGCATT 
AAGCCAGAGTAATTACAGGGTTCACCTTATTTATTTCCCTTTTCTTAAAGATTACTGTTC 
TGTGCTGCCTGTTTTCTAGTGTCTAAAAACCATTTCTTCATGTATTTTWGATATTTAAGG 
TTCAAACCAGTCTGTTTTACT 
 
 
Figure 9: rs230539 Sequence.  
The FASTA sequence indicates the position of the variant rs230539 in red. Blue 
text shows the other variants and the sequences that are underlined are primers. 
 
 
 
3.1.3 DNA detection 
 
Amplification of genomic DNA was performed using PCR followed by 
analysis of the products using agarose gel electrophoresis. PCR 
amplification was performed with different primer concentrations (0.2, 0.5 
or 1 µM) to find the optimum concentration for this set of experiments 
(Figure 10). 
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3.1.3.1 PCR gel electrophoresis  
 
 
 
Figure 10: PCR product following amplification with NFB primers generated 
using different primer concentrations 0.2 – 1μM  
 
Figure 10 shows that the calculated fragment size of the PCR product was 
195 bp, which was predicted to be 206 bp. PCR products were amplified 
with different primer concentrations: 0.2, 0.5 and 1 μM in order to choose 
the best primer concentration for further experiments.  A primer 
concentration of 0.2 μM was used in all subsequent experiments as it gave 
the cleanest band at the correct size, with no additional smaller bands as 
is evident when using 0.5 and 1.0 M which show faint or smeared bands 
(Figure 10). 
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3.1.3.2 PCR with restriction enzymes 
 
The amplified fragments were cut with an enzyme known to cleave DNA at 
the SNP site of interest (rs230539). Images of gels showing restricted and 
unrestricted PCR product using HpyCH4iii with different periods of 
incubation (A) 1 hour, (B) 4 hours and (C) 24 hours. Figure 11(A, B and C) 
showed there was no digestion of the fragment.  
 
Figure 11: A1 hr incubation with HpyCH4iii at 37°C, the restriction was carried 
out for 4 hr at 37°C (B) and 24 hr (C). 
The uncut size of the calculated fragment size was 197 bp which was close 
to the predicted size of 206 bp, whereas the product with HpyCH4iii 
enzyme increased in size to around 260 bp when incubated for 1 hour 
(Figure 12A).  The gel showed that there was no digestion with this 
enzyme (HpyCH4iii) after 4 hr incubation at 37oC and that the fragment 
size increased from 206 bp to 260 bp when the sample was incubated for 
1 hour and to 380 bp after 24 h incubation (Figure 11). This might indicate 
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binding of the enzyme to the substrate (Figure 11A and 11C). Also, Figure 
11B showed that the digestion did not work and the calculated fragment 
size was 197 bp which was predicted to be 206 bp.  
Therefore, other restriction enzymes were used: Alu1 and PvuII, and the 
results are shown in Figure 12. 
 
 
Figure 12: Restriction with HpyCH4iii, Alu1 and PvuII incubated for one hour at 
37°C. 
The results show that there was no digestion of the product after using 
enzymes HpyCH4iii (which supports the result shown in Figure 11) and 
PvuII, whereas it appears that Alu1 has cut the product (Figure 12). NEB 
cutter predicted the PCR product was digested by two restriction enzymes 
specific for the region amplified, which are HpyCH4iii and Alu1. There are 
two bands in the Alu1 lane and their size is 164 bp and 219 bp. Alu1 
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should cut in one site at AGCT length 175/177bp. According to HpyCh4iii it 
is larger than 206 bp, and its size is 293 bp. 
According to our results from the gel, the fragments were uncut, by 
HpyCh4iii as shown in Figures 11 and 12. The PCR product when digested 
with HpyCH4iii increased in size to around 290 bp. However, these 
restriction enzymes were predicted to digest according to the NEB cutter 
software except PvuII but in vitro it appears that this was not 
demonstrated in these experiments. To further investigate the sequence, 
the DNA samples were sent for sequencing. 
 
3.1.4 DNA Sequencing 
 
3.1.4.1 PCR purification and DNA detection 
 
A sample of DNA was purified using the Qiagen MinElute Reaction Cleanup 
Kit and the size confirmed by resolution in an agarose gel (Figure 13). 
 
Figure 13: PCR purification of gDNA via gel electrophoresis  
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Figure 13 shows the fragment size for the PCR product alongside the DNA 
ladder, after purification, the calculated fragment size was 199 bp which 
was predicted to be 206 bp and the sequence output is shown in Section 
3.1.4.2.  
 
3.1.4.2 Sequence output 
 
DNA sequencing was used because the digestion of the fragment with 
restriction enzymes was unsuccessful. Therefore, the sample was sent to 
Dundee University for sequencing and shown below is the sequence output 
(Figure 14). 
 
 
Figure 14: (A) Predicted DNA sequence and (B) DNA sequence obtained from 
Dundee. The highlighted regions show the restriction site for enzymes HpyCH4iii 
(green) and Alu1 (blue). 
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Figure 15: Sequence Alignment. 
The nucleotides in blue show regions where the nucleotide sequence is incorrect 
and the position of the * shows missing data.  The highlighted region shows the 
sequence of the SNP is A. The nucleotides in red are the published sequence and 
the lower black text is the amplified sequence output. 
 
 
The predicted sequence and the sequence obtained for the Dundee 
sequencing lab were compared and are presented in Figure 15. Sequence 
alignment was used to compare between the two sequences and to 
determine their similarity. According to above aligned sequences 
(predicted sequence in red and obtained sequence from Dundee in black), 
there is a mismatch (as shown in blue) and a couple of gaps (represented 
by *) and this may affect the identity.  Similarity between two sequences 
is 94% (i.e. 12 of 206 nucleotide mismatch) when adjustments are made 
to alignment when incorporating the gaps. 
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Figure 16: Restriction sites for enzymes HpyCH4iii and Alu1.  
The highlighted regions show the restriction site for enzymes HpyCH4iii (green) 
and Alu1 (blue). 
With time constraints it was not possible to follow this up further in this 
study but work progressed by examining the way that the NFĸB and HIF1α 
genes could be regulated in response to glucose concentration. 
 
3.2 RNA Detection 
 
To investigate the regulation and expression of NFĸB1, mRNA level was 
measured following exposure of U937cells to high glucose concentrations. 
cDNA was amplified with 0.2 µM NFĸB, 0.2 µM HIF1α and 1 µM β2-
microglobulin primers after 24 hours incubation in different glucose 
conditions (5.5 mM, 20 mM and 40 mM) to determine any changes in the 
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level of NFĸB, HIF1α and β2-microglobulin in response to different glucose 
concentrations.   
RNA was extracted using trizol and purified from U937 cells (See Figure 
17). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: RNA gel electrophoresis of RNA bands using trizol (ratio: 2.4) 
 
Figure 17 details that the RNA bands (18S and 28S) were observed in 
Lane 2: 2 µg RNA loaded to well, whereas in Lane 1: 1 µg RNA was loaded 
and their RNA bands (18S and 28S) are not clear. This could be due to 
there not being enough RNA loaded in Lane 1 as only 1 µg RNA was used. 
Whereas in Lane 2, 2 µg RNA was used and the two faint bands for RNA, 
which are 28S and 18S ribosomal RNAs, were visible. Also RNA was 
degraded as evident with the band identified. 
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cDNA samples were prepared from each of the RNA samples from U937 
cells treated as specified in the text (Section 2.4) and amplified with β-
Actin primers (Table 6) (in Figure 18) to check the level of the respective 
mRNA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Gel electrophoresis for cDNA amplification with 0.5 µM β-Actin primers 
following different incubation times, with and without H2O2, (C is for a control). 
 
Figure 18 shows the gel electrophoresis for cDNA amplification with β-
Actin following different incubation times of 0, 30, 60 and 180 minutes, 
with and without H2O2 (10 µM). There is a clear band observed and it was 
calculated to be 381 bp in size which was predicted to be 387 bp with 
control condition (denoted by C) during incubation times of 30, 60 and 180 
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minutes. In addition, there was also a band detected after incubation in 
the presence of H2O2 for 0, 30, 60 and 180 minutes.  
cDNA amplification with 0.5 µM β-Actin was repeated on the following day 
with different set of cDNA samples and results are shown in Figure 19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Gel electrophoresis for cDNA amplification with 0.5µM β-Actin primers 
with different incubation times with and without H2O2. 
 
Figure 19 shows the gel electrophoresis for cDNA amplification with 0.5 µM 
β-Actin with 0 30, 60 and 180 minutes incubation with and without H2O2. 
After repeating this experiment several times with 0.5 µM β-Actin, it did 
not work in the same way as Figure 18, as shown in Figure 19 and there 
was no evidence of amplification. 
 
75 
 
 
 
3.2.2 cDNA amplification with HIF1α and NFĸB 
primers 
 
U937 cell cDNA was amplified with HIF1α primer with/without the Taq in 
order to check that there was not any contamination and to confirm the 
fragment size (Figure 20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Gel electrophoresis for PCR samples with HIF 1α primers 
 
Figure 20 shows gel electrophoresis for cDNA amplification with HIF1α. 
First lane (From right to left) was the ladder, lane 2 was HIF1α with no 
Taq, and lane 3 was HIF1α with Taq.  HIF1α with Taq shows a clear band 
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with size around 181 bp, which was at the correct size predicted from 
sequence information. 
 
cDNA amplification with NFĸB primers was then carried out to check the 
band size of this product. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21:Gel electrophoresis cDNA amplification with NFKB primers 
 
Figure 21 shows cDNA amplification with NFĸB primer and there was band 
sized at 199 bp. Then, the test samples were then amplified with NFĸB 
and HIF1α with and without H2O2 at same concentrations as before. 
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3.2.3 cDNA amplification with NFĸB and HIF1 α 
primers (Control (C) and H2O2) 
 
RNA extraction was followed by cDNA was amplified with NFĸB and HIF1 α. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22:Gel electrophoresis cDNA amplification with NFĸB and HIF1α primers 
. 
Figure 22 shows the gel electrophoresis for cDNA amplification with NFĸB 
and HIF1α, with and without H2O2 after 0 minutes. Lane 1(From right to 
left): ladder, Lane 2: negative control, Lane 3: Control (cDNA used 
previously, Figure 21), Lane 4: Control (fresh cDNA), Lane 5: C0.0 min 
with NFĸB, Lane 6: H2O2 with NFĸB, Lane 7: Control (cDNA used 
previously, Figure 20), Lane 8: Control (fresh cDNA), Lane 9: C0.0 min 
with HIF1α and Lane 10: H2O2 with HIF1α. This experiment worked for 
HIF1α as a band with HIF1α was evident at 181 bp for control (0 minutes). 
However, this was not the case with NFĸB as no bands were observed with 
78 
 
any of the conditions tested.  The (Control) was cDNA sample from 10 
million cells that was prepared previously. Also, cDNA sample from 10 
million cells that freshly made. 
To repeat the experiment shown in Figure 22, cDNA amplification with 
HIF1α was conducted to check the gene expression during different 
incubation times with and without H2O2.   
 
 
 Figure 23: Gel electrophoresis for cDNA amplification with HIF1 α primers with 
different incubation times with and without H2O2 
Figure 23 shows the gel electrophoresis result for cDNA amplification with 
0.2 µM HIF1α during different incubation times: 0 minute, 30 minutes, 60 
minutes and 180 minutes with and without H2O2 (10 µM). The expression 
of HIF1α was evident with incubation times of 0 and 180 minutes without 
H2O2 (181 bp).   
As the cDNA amplification with β-Actin primers did not work (Figure 19), 
amplification with β2-microglobulin primers was carried out as it is another 
type of housekeeping gene.  
 
 
79 
 
 
3.2.4. cDNA amplification with NFKB, HIF1 α and β2-
microglobulin primers with different glucose 
concentrations 
 
 
 
Figure 24: Gel electrophoresis for cDNA amplification with 0.2 µM NFĸB and 
HIF1α primers in different glucose concentrations. NFĸB was not expressed in this 
cell. HIF1α in lanes 12, 13 and 14 was expressed with size 181 bp. The table 
shows the lane number and the samples. 
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cDNA amplification with HIF1 α and β2-microglobulin primers with different 
glucose concentrations is shown below in Figure 25. 
 
Figure 25: Gel electrophoresis for cDNA amplification with 0.2 µM HIF1α and β2-
microglobulin primers in different glucose concentrations. HIF1α was expressed 
and shown in lanes 2, 3, 4 and 5. Lane 8 shows the expression of β2-
microglobulin. 
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Figures 24 and 25 show images of electrophoresis gels for cDNA 
amplification with NFĸB, HIF1α and β2-microglobulin in different glucose 
concentrations, which were 5.5, 20 and 40 mM. NFĸB was not shown to be 
expressed in this cell line, whereas bands for HIF1α expression were 
identified and calculated to be 181 bp in size, which is the correct size. In 
addition, there was a clear band for β2-microglobulin with normal glucose 
condition (5.5 mM) and the calculated band size was 251 bp, which 
aligned with the predicted size but this was not seen in the other 
experimental conditions. 
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Chapter 4: Discussion 
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4.1 SNP detection 
 
To identify the genetic variations in the NFκB1 gene that are associated 
with diabetes, the NFκB1 gene was examined and one SNP was selected 
within the NFκB gene that has been identified and associated with diabetes 
(Ensemble, 2013). This was rs230539. According to the genotype data 
from Ensemble website, rs230539 is an intronic variant and located in 
chromosome 4 at 4q24 in position 103495532. Rs230539 (G/A) where this 
polymorphism was reported to be associated with type 2 diabetes (Kent et 
al., 2014). There are different reports illustrating that genetic variation in 
the intron region are involved in changes to transcript processing (Kent et 
al., 2014). Through a splicing step, introns need to be taken off from the 
pre-mRNA. Intronic SNPs may have an effect on gene expression and also 
may affect transcriptional regulation. Transcriptional regulation is a 
process that can adjust the transformation of DNA to RNA. As a result of 
that, it regulates the activity of the gene (Lewin 2004). 
NFκB1 polymorphism was determined by using restriction fragment length 
polymorphism (RFLP) with different restriction enzymes. Initially the 
HpyCH4iii restriction enzyme was used (incubated for 60 minutes), but the 
enzyme did not digest the PCR product and the size of the band increased 
to 260 bp from 206 bp and there was no obvious reason for this. 
Therefore, the experimental conditions were changed to 4 hours and 24 
hours incubations. The fragment size when incubated for 4 hours was 217 
bp which is consistent with what was expected, whereas with an overnight 
incubation, the fragment size increased to 359 bp. This may be due to 
binding of DNA to the enzyme  according to the manual from New England 
Biolabs (New-England-Biolabs-Inc. 2010). As larger bands are shown in 
the gel after digestion, this may due to binding of enzyme to the 
substrate.  Also, over digestion of more than 4 hours is not recommended 
and may cause changes in the fragment size (New-England-Biolabs-Inc. 
2010).  However, this does not explain the result found after 1hour 
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restriction.  This increased size may result from alteration of band size due 
to dimer formation. During the last step of PCR, which is cooling step, 
hybridisations may occur (New-England-Biolabs-Inc. 2010). 
Another two enzymes, Alu 1 and PvuII were used (one-hour incubation 
according to manufacture’s protocol) and run alongside the HpyCH4iii 
enzyme on the same gel. According to the results for PvuII there was no 
cleavage of the DNA, this is consistent with predicted sequence 
information. The PCR product appeared to have been partially digested 
with Alu1. There are two bands in the Alu1 lane and their size was 
recorded as 164 bp and 219 bp. Alu1 should cut in one site at AGCT length 
175/177 bp. This may due to restriction enzyme digestion not fully 
digesting the DNA and therefore evidence of uncut and cut DNA remains.  
This could be due to the incubation time not being long enough or too few 
units of the enzyme used. After sequencing the PCR product, results show 
the similarity between two sequences is around 94%. According to 
sequencing result, HpyCH4iii enzyme did not cut because of the wild type 
(A) is present. Alu1 did not cut because it will be heterozygous, which 
means one of the DNA strand has restriction site, which is one with right 
sequence and one does not due to change in the sequence.  This means 
that two sequences have the same length, similar gene sequences and 
have similar structures. As no one has examined the gene databases to 
identify the SNP rs230539 in NFκB before in U937 cells, therefore, this 
finding is novel and an interesting finding in this study. 
 
 
4.2 Standardisation of NFĸB, RT-PCR and the effect 
of different glucose concentrations 
 
Initially, 1x104 U937 cells/ml was used in 6 well plates, which was found 
to be not a sufficient number of cells, and may explain why the RNA 
concentrations were initially so low. Therefore, number of U937 cells was 
optimised to provide a sufficient RNA concentration and quality. After 
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using 1x 107 U937 cells and RNA extracted using Trizol reagent.  The RNA 
concentration was high (2.4μg/μl). In addition, the RNA concentrations 
were high, but bands were not clear and RNA quality was low. This may 
due to only 1 μg of the sample being added and this was not enough. In 
the other lane, 2 μg was used and the two bands for RNA, which are 28S 
and 18S ribosomal RNAs, were visible.  However, it seems that the RNA 
had degraded partially, which is evident by the smeared appearance and 
lack of sharp bands.  (Thermo Fisher 2015) .  
RT-PCR was used for the amplification of cDNA with β-Actin, HIF1-α, β2-
microglobulin and NFĸB. β-Actin worked the first time the experiment was 
conducted but, when it was repeated, it did not work and this may be due 
to storage of RNA that may affect the RNA quality and/or it may degraded 
due to inherent enzyme contamination. Moreover, the amplification of 
cDNA with HIF1-α at the start of the experiment (0 minute) without H2O2 
worked with a band observed at 181 bp, whereas no band was observed 
when incubated with H2O2 0 minute. This may indicate that the number of 
surviving cells was low or that H2O2 may cause cellular dysfunction and the 
cells to die (Coyle et al. 2006) even after the very short exposure. 
Furthermore, the NFĸB PCR product was not detected during different 
incubations with various glucose concentrations, whereas, HIF1α 
expression appeared to decrease during high glucose concentrations 
(40mM). The NFĸB PCR product was not detected, this may lead to 
incubation times not being long enough and that longer than 24 hours 
should be investigated. In other research with U937 (Guha et al. 2000), 
the regulation of TNFα and NFĸB via exposure of the cells to chronic high 
glucose concentrations is reported after 2 days incubation in the absence 
of further stimulation. These observations will need to be verified by 
repeating these experiments. It appears that there is perhaps something 
about these cells that do not lend themselves to this experimental 
approach. This may be due to the fact that U937 cells are a suspension 
cell line and are generally used following stimulation with LPS (E. coli 
Lipopolysaccharide) (Baek et al., 2009). In addition, U937 can first 
differentiate into macrophage by incubation with 10 ng/ml of PMA (phorbol 
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12-myristate 13-acetate) for 24 hours and also can be activated with 
1µg/ml of LPS (E-coli lipopolysaccharide) for 6 hours to copy inflammatory 
response of stimulated macrophages (Ghosh et al. 2010). 
There is a study shows that, culturing U937 cells treated with LPS in 
medium containing high glucose for 2 weeks or longer caused an 
important increase in gene expression and caused stimulation of Matrix 
metalloproteinase-1 (MMP-1) and mononuclear cells of tumor necrosis 
factor-α (TNFα). LPS and high glucose increase CD14 in U937 cells by 
prompting the transcription activity of NFĸB and AP-1 (Nareika et al. 
2008).In this research, monocyte was used as it is circulate in blood 
before entering tissue and expresses different cytokines. Several studies 
with Thp1 show that high glucose stimulates monocytes and encourage 
the TNF-α activation via NFĸB (Shanmugam et al. 2003). U937 cells have 
been used in several studies to investigate different biological approaches 
linked to monocyte and macrophage function such as monocytic 
differentiation (Baek et al., 2009).  
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4.3 Conclusion 
 
The essential conclusions from this work to date are: 
1. RFLP and sequencing demonstrated that U937 cells express the wild 
type form of rs230539. 
2. Restriction digestion with HpyCH4iii was problematic if 4 hour 
incubation is not used. 
3. U937 cells have the potential for use as a model for determining the 
effect of glucose concentration on gene expression but the following 
must be considered with further studies: 
a. The role of stimulation of the cells 
b. The repeatability of the observed changes in expression of NFĸB 
and HIF1α 
c. The effect of duration of exposure to the test conditions on the 
results. 
 
 4.4 Future Work 
  
If time allowed there are a number of ways this work could be extended.  
For example, U937 cells could be cultured under different glucose 
concentrations and incubated for more than 24 hours to determine the 
role of NFκB activation. U937 cells could be treated with phorbol 12-
myristate 13-acetat (PMA) for 12 to 24 hours to activate monocytic 
differentiation. 
Another example U937 cells could be cultured under hypoxia (<5%) in a 
range of glucose concentrations to address the biological significance of 
NFκB activation. Afterwards, the supernatants would be analysed for the 
protein level expression using ELISA. The cells would be incubated alone 
(control cells) and /or incubated with H2O2 to show the response to the 
oxidative stress  and to demonstrate the effect of oxygen on inflammatory 
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mediators responsible for the vascular complications in diabetes (Nareika 
et al. 2008).  Western blot could be used to test for an increase in NFĸB 
proteins, but also to determine the protein expression of inflammatory 
cytokines with high glucose concentrations and measure the changes in 
nuclear NFĸB after incubation in high glucose concentrations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
89 
 
 
 
 
 
 
 
 
 
 
References 
 
 
 
 
 
 
 
 
 
 
 
 
90 
 
Ahmad, S., 2013. Diabetes: An Old Disease, a New Insight, Springer 
Science & Business Media 
Aiello, LP., 2002, The potential role of PKC in diabetic retinopathy and 
macular edema, Survey of Ophthalmology, 47(2), pp. S263-S269. 
Alghadyan, AA., 2011, Diabetic retinopathy – An update, Saudi Journal of 
Ophthalmology, 25(2), pp. 99-111.  
Allman, T., 2008. Diabetes, Infobase Publishing.  
Andreasen, A. Meghan, K. Ronan, M. Kirsten, M. and Bente, K., 2011. 
Type 2 diabetes is associated with altered NF-κB DNA binding activity, JNK 
phosphorylation, and AMPK phosphorylation in skeletal muscle after LPS. 
PloS one, 6(9), p.e23999.  
Atkinson, M., 2012. The pathogenesis and natural history of type 1 
diabetes. Cold Spring Harbor perspectives in medicine, 2(11), pp.1–18.  
Aveleira, C., 2009, The role of inflammatory mediators in retinal 
microvascular dysfunction: implications for the blood-retinal barrier 
breakdown in diabetic retinopathy. University of Coimbra, Coimbra, pp.9–
181.  
Baek, Y. Haas,S. Hackstein, B. Holger, G. Hernandez, Santana, M. 
Lehrach, H . Sauer, S & Seitz, H., 2009.  Identification of novel 
transcriptional regulators involved in macrophage differentiation and 
activation in U937 cells, BMC Immunology, 10:18, pp. 1-15. 
Balasubramanyam, M, Rema, M & Premanand, C., 2002, Biochemical and 
molecular mechanisms of diabetic retinopathy, Current Science, 83(12), 
pp. 1506-1514. 
Bergers, G. Song, S., 2005. The role of pericytes in blood-vessel formation 
and maintenance. Neuro-Oncology, 7(4), 452–464. 
Blom, N., Gammeltoft, S., and Brunak, S., 2013. Sequence- and structure-
based prediction of eukaryotic protein phosphorylation sites., NetPhos 2.0 
server. [online] Journal of Molecular Biology. Available from: 
http://www.cbs.dtu.dk/services/NetPhos/ [Accessed september 2013]. 
Brownlee, M., 2001, Biochemistry and molecular cell biology of diabetic 
complications, Nature, 414(6865), pp. 813-820. 
Brownlee, M., 2005, The pathobiology of diabetic complications: A unifying 
mechanism, Diabetes, 54(6), pp. 1615-1625.  
Cade, W.T., 2008. Diabetes-related microvascular and macrovascular 
diseases in the physical therapy setting. Physical therapy, 88(11), 
pp.1322–1335. 
 
91 
 
Catrina, S. Kensaku, O. Teresa, P. Kerstin, B. & Lorenz, P., 2004. 
Hyperglycemia Regulates Hypoxia-Inducible Factor-1α - Protein Stability 
and Function, Diabetes 53(12), pp.3226–32. 
Chakrabarti, S., 2007, Diabetic retinopathy: From pathogenesis to 
treatment, Hindawi Publishing Corporation, New York, NY. 
Chen F., 2014. NFKB1 (nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 1). [online] Atlas of Genetics and Cytogenetics in 
Oncology and Haematology. Available from: 
http://atlasgeneticsoncology.org/Genes/NFKB1ID323.html [Accessed 
September 2013].  
Chen, S, Xue, Y, Zhang, X, Wu, Y, Pan, J, Wang, Y & Cheng, J., 2005, A 
new human acute monocytic leukaemia cell line SHI-1 with t(6;11) 
(q27;q23), p53 gene alterations and high tumorigenicity in nude mice, 
Haematologica, 90(6), pp. 766-775. 
Chistiakov, DA., 2011, ‘Diabetic retinopathy: Pathogenic mechanisms and 
current treatments’, Diabetes & Metabolic Syndrome, 5(3), pp. 165-172.    
Coyle, C. H., Martinez, L. J., Coleman, M. C., Spitz, D. R., Weintraub, N. 
L., & Kader, K. N., 2006. Mechanisms of H2O2-induced oxidative stress in 
endothelial cells. Free radical biology & medicine, 40(12), pp.2206–2213. 
Detrick, B., & Hooks, J. J., 2010. Immune regulation in the retina. 
Immunologic Research, 47(1-3), 153–161. 
Diabetes UK, 2010. Key statistics on diabetes. Diabetes, 692(March), 
pp.1–21.  
Di Iorgi, N., Napoli, F., Allegri, A. E. M., Olivieri, I., Bertelli, E., Gallizia, A.,  
Maghnie, M., 2012. Diabetes Insipidus; Diagnosis and Management. 
Hormone Research in Paediatrics, 77(2), pp.69–84.  
Donnelly, R., Idris, I., & Forrester, J. V., 2004. Protein kinase C inhibition 
and diabetic retinopathy: a shot in the dark at translational research. The 
British Journal of Ophthalmology, 88, pp. 145-151. 
Duh, E. & Aiello, L.P., 1998 Perspectives in Diabetes. , pp.1899–1906. 
Ensembl. 2013. [online] Wellcome Trust Sanger Institute. Available from: 
http://www.ensembl.org/Homo_sapiens/Search/Results?species=Homo_s
apiens;idx=;q=NFKB1 [Accessed February 2013 2013]. 
Faideau, B., Larger, E., Lepault, F., Carel, J. C., & Boitard, C.., 2005. Role 
of beta-cells in type 1 diabetes pathogenesis. Diabetes, 54, pp.s87–s96. 
Fhearraigh, S., Signalling pathways involving Protein kinase C (PKC) | 
Abcam. Available at: http://www.abcam.com/cancer/signaling-pathways-
involving-pkc [Accessed November 3, 2015]. 
Fowler, MJ 2008, ‘Microvascular and macrovascular complications of 
diabetes, Clinical Diabetes, 26(2), pp. 77-82.  
92 
 
Gao, W., Ferguson, G., Connell, P., Walshe, T., Murphy, R., Birney, Y. A., 
Cahill, P. A.., 2007. High glucose concentrations alter hypoxia-induced 
control of vascular smooth muscle cell growth via a HIF-1alpha-dependent 
pathway. Journal of molecular and cellular cardiology, 42(3), pp.609–19.  
Gene cards. 2013. [online] Weizmann Institute of Science. Available from: 
http://www.genecards.org/cgi-
bin/carddisp.pl?gene=NFKB1&search=NFKB1 [Accessed February 2013 
2013]. 
Ghosh, C. C., Ramaswami, S., Juvekar, A., Vu, H.-Y., Galdieri, L., 
Davidson, D., & Vancurova, I., 2010. Gene-specific repression of 
proinflammatory cytokines in stimulated human macrophages by nuclear 
IκBα. Journal of immunology (Baltimore, Md.: 1950), 185(6), pp.3685–93.  
Guha, M., Bai, W., Nadler, J. L., & Natarajan, R., 2000. Molecular 
Mechanisms of Tumor Necrosis Factor   Gene Expression in Monocytic Cells 
via Hyperglycemia-induced Oxidant Stress-dependent and -independent 
Pathways. Journal of Biological Chemistry, 275(23), 17728–17739. 
Hammes, H.-P., Feng, Y., Pfister, F., & Brownlee, M., 2011. Diabetic 
Retinopathy: Targeting Vasoregression. Diabetes, 60(1), pp.9–16.  
Kerry, A., 2013. Retina. [online] Assil Eye Institute. Available from: 
http://www.assileye.com/los-angeles/diabetic-retinopathy.htm [Accessed 
15/4/2013 2013]. 
King, GL 2008, The role of inflammatory cytokines in diabetes and its 
complications, Journal of Periodontology, 79(8), pp. 1527-1534. 
Kowluru, RA, Zhong, Q & Kanwar, M., 2010, Metabolic memory and 
diabetic inflammatory mediators in retinal pericytes, Experimental Eye 
Research, 90(5), pp. 617-623.  
Lang, G., 2007, Treatment of diabetic retinopathy with protein kinase C 
subtype beta, In W. Behrens-Baumann (eds), Diabetic retinopathy, 
Kanger, Geneva, pp. 11-32.  
Larger, E., Carel, J. C., & Boitard, C., 2005. Role of Beta -Cells in Type 1 
Diabetes Pathogenesis. Diabetes, 54(1), S87–S96. 
Lebovitz, HE., 2001, Effect of the postprandial state on non-traditional risk 
factors, American Journal of Cardiology, 88(6A), pp. 20H-25H.Lewin, B., 
2004. Gene Expression. Gene Expression, 3(1), pp.64–75 
Lin, L., DeMartino, G.N. & Greene, W.C., 1998. Cotranslational Biogenesis 
of NF-κB p50 by the 26S Proteasome. Cell, 92(6), pp.819–828.  
Ma, R.C. & Chan, J.C., 2013. Type 2 diabetes in East Asians: similarities 
and differences with populations in Europe and the United States. Ann N Y 
Acad Sci, 1281, pp.64–91.  
93 
 
Marumo, T., Schini-Kerth, V.B. & Busse, R., 1999. Vascular endothelial 
growth factor activates nuclear factor-kappaB and induces monocyte 
chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes, 
48(16), pp.1131–1137. 
Nareika, A., Im, Y.-B., Game, B. A., Slate, E. H., Sanders, J. J., London, S. 
D., Huang, Y., 2008. High glucose enhances lipopolysaccharide-stimulated 
CD14 expression in U937 mononuclear cells by increasing nuclear factor 
kappaB and AP-1 activities. The Journal of Endocrinology, 196(1), 45–55. 
National center for biotechnology information (NCBI)., 2012. [online] U.S. 
National Library of Medicine. Available from: 
http://www.ncbi.nlm.nih.gov/snp/?term=NFKB1 [Accessed February 
2013]. 
Nehme, A & Edelman, J., 2008, Dexamethasone inhibits high glucose -, 
TNF, and IL-1-induced secretion of inflammatory and angiogenic mediators 
from retinal microvascular pericytes, Investigative Ophthalmology & Visual 
Science, vol. 49 no. 5, pp. 2030-2038.  
New-England-Biolabs-Inc., 2010. Restriction Enzyme Troubleshooting 
Guide, NEB., pp.1–2. 
Nishikori, M., 2005, Classical and alternative NF-kB activation pathways 
and their roles in lymphoid malignancies, Journal of Clinical & 
Experimental Haematopathology, vol. 45 no. 1, pp. 15-24.     
Paneni, F., Beckman, J., Creager, M., & Cosentino, F., 2013. Diabetes and 
vascular disease: pathophysiology, clinical consequences, and medical 
therapy: part I. European heart journal, 34(31), pp.2436–43.  
Patel, S & Santani, D., 2009, Role of NF-kB in the pathogenesis of diabetes 
and its associated complications, Pharmacological Reports, vol. 61, pp. 
595-603. 
Primer quest., 2013. [online] Integrated DNA Technologies. Available 
from: http://eu.idtdna.com/PrimerQuest/Home/Index [Accessed October 
2013]. 
Rohilla, A, Kumar, R, Rohilla, S & Kushnoor, A., 2012, Diabetic 
retinopathy: Origin and complications, European Journal of Experimental 
Biology, vol. 2 no. 1, pp. 88-94. 
Romzova, M., Hohenadel, D., Kolostova, K., Pinterova, D., Fojtikova, M., 
Ruzickova, S., Cerna, M., 2006. NFKB and Its Inhibitor IKB in relation to 
type 2 diabetes and Its Microvascular and Atherosclerotic Complications. 
Human Immunology, 67(9), 706–13.   
Roy, H., 2006. Vascular Endothelial Growth Factors (VEGFs) - Role in 
Perivascular Therapeutic Angiogenesis and Diabetic Macrovascular 
Disease. Department of Biotechnology and Molecular Medicine, University 
of Kuopio, pp. 1-81. 
94 
 
Sandhu, M. S., Weedon, M. N., Fawcett, K. A., Wasson, J., Debenham, L., 
Daly, A., Walker, M., 2009. Common variants in WFS1 confer risk of type 
2 diabetes. Europe PMC Funders Group, 39(8), pp.951–953. 
Sandip, P.A.D., Santani, 2009. Role of NF-KB in the pathogenesis of 
diabetes and its associated complications. Pharmacological Reports, 
61(1734-1140), pp. 595-603. 
Sankar, G. Michael J. M, & Elizabeth B. K., 1998. NF-κB AND REL 
PROTEINS: Evolutionarily Conserved Mediators of Immune Responses. 
Immunology, 16: 225-26, p.10.1146.  
Saxena, S., 2012, Diabetic retinopathy, 1st edn, Jaypee Brothers Medical 
Publishers, New Delhi. 
Schröder, S., Palinski, W. & Schmid-Schönbein, G.W., 1991. Activated 
monocytes and granulocytes, capillary nonperfusion, and 
neovascularization in diabetic retinopathy. The American journal of 
pathology, 139(1), pp.81–100. 
Shanmugam, N., M. A. Reddy, M. Guha, and R. Natarajan., 2003. High 
Glucose-Induced Expression of Proinflammatory Cytokine and Chemokine 
Genes in Monocytic Cells. Diabetes, 52(May), pp. 1256–1264. 
Semenza, G.L., 2001. HIF-1 and mechanisms of hypoxia sensing. Current 
Opinion in Cell Biology, 13(2), pp.167–171. 
Serono, M., 2011. Hormones and Me Diabetes Insipidus Hormones and 
Me. Living science, transforming lives. (A. P. E. Group, Ed.), Australia: 
Merck Serono Australia Pty Ltd. 
Sivaprasad, S, Gupta, B, Crosby-Nwaobi, R & Evans, J., 2012. Prevalence 
of diabetic retinopathy in various ethnic groups: A worldwide perspective, 
Survey of Ophthalmology, 57(4), pp. 347-370. 
Song, M.K., Roufogalis, B.D. & Huang, T.H.W., 2012. Modulation of 
diabetic retinopathy pathophysiology by natural medicines through PPAR-
γ-related pharmacology. British journal of pharmacology, 165(1), pp.4–19.  
 
Song, S., Chen, D., Lu, J., Liao, J., Luo, Y., Yang, Z., Wang, J., 2011. 
NFκB1 and NFκBIA polymorphisms are associated with increased risk for 
sporadic colorectal cancer in a southern Chinese population. PloS one, 
6(6), e21726, pp. 1-10.  
Stratton, I. M., Adler, a I., Neil, H. a, Matthews, D. R., Manley, S. E., Cull, 
C. a, Holman, R. R., 2000. Association of glycaemia with macrovascular 
and microvascular complications of type 2 diabetes (UKPDS 35): 
prospective observational study. BMJ (Clinical research ed.), 321(7258), 
pp.405–412.  
95 
 
Tadhg, Colm., 2006. Bioinformatic detection and analysis of functionally 
important genetic variation, Molecular and Cellular Therapeutics, Royal 
College of Surgeons in Ireland. 
Tarr, J. M., Kaul, K., Chopra, M., Kohner, E. M., & Chibber, R., 2013. 
Pathophysiology of diabetic retinopathy. ISRN ophthalmology, 2013 (146), 
p.13.  
Thermo Fisher, S., 2015. RNA Sample Collection, Protection, and Isolation 
Support—Troubleshooting. Available at: 
https://www.thermofisher.com/uk/en/home/technical-resources/technical-
reference-library/nucleic-acid-purification-analysis-support-center/rna-
sample-collection-protection-isolation-support/rna-sample-collection-
protection-isolation-support-troubleshooting.html [Accessed November 28, 
2015]. 
Vincze, T., Posfai, J. & Roberts, R.J, 2014. Nebcutter v2.0. [online] New 
England Biolabs. Available from: http://tools.neb.com/NEBcutter2/ 
[Accessed October 2013]. 
Williamson, R.T., 2009. Causes of diabetes. 1909. The Practitioner, 
253(1718), p.37. 
Xiao, H., Gu, Z., Wang, G., & Zhao, T., 2013. The possible mechanisms 
underlying the impairment of hif-1α pathway signaling in hyperglycemia 
and the beneficial effects of certain therapies. International Journal of 
Medical Sciences, 10(10), pp.1412–1421. 
Zhang, W, Liu, H, Al-Shabrawey, M, Caldwell, RW, & Caldwell, RB., 2011. 
Inflammation and diabetic retinal microvascular complications, Journal of 
Cardiovascular Disease Research, 2(2), pp. 96-103. 
